[{"orgOrder":0,"company":"Mundipharma","sponsor":"Biosolution","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mundipharma, Biosolution to market CartiLife in South Korea","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Undisclosed","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"Chondrocytes","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Mundipharma","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mundipharma \/ Biosolution Co. Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Mundipharma \/ Biosolution Co. Ltd"},{"orgOrder":0,"company":"Teoxane SA","sponsor":"Revance Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Revance Announces Transformative Aesthetics Portfolio Transaction with Exclusive U.S. Distribution Agreement of FDA-Approved Dermal Fillers from TEOXANE SA","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"Hyaluronic Acid","moa":"Sodium channel alpha subunit","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Teoxane SA","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Teoxane SA \/ Revance Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Teoxane SA \/ Revance Therapeutics"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ultragenyx and Kyowa Kirin Announce Submission of Supplemental Biologics License Application to U.S. FDA for Crysvita\u00ae (burosumab) for Tumor-Induced Osteomalacia (TIO)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Burosumab","moa":"FGF23","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Ultragenyx Pharmaceutical","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ultragenyx Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ultragenyx Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Medivir","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medivir\\'s Phase II Study of MIV-711 in Patients With Osteoarthritis Published in Annals of Internal Medicine","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"MIV-711","moa":"Cathepsin K","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Medivir","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Medivir \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Medivir \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cadent Therapeutics Announces FDA Acceptance of IND Application for CAD-1883 for Spinocerebellar Ataxia (SCA)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Cad-1883","moa":"Calcium-sensitive potassium ion channel PAM","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fulcrum Therapeutics Receives Orphan Drug Designation for Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) and Announces Expanded Patent Portfolio","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Losmapimod","moa":"Mapk\/p38 alpha","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fulcrum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ra Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ra Pharmaceuticals Announces Publication of Zilucoplan Phase 2 gMG Trial Results in JAMA Neurology","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Zilucoplan Sodium","moa":"Completent C5","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Ra Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ra Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Ra Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Dyve Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dyve Biosciences Announces First Patient Enrolled in TARGETS Study for Treatment of Acute Gout","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"DYV-700","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Dyve Biosciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Lotion","sponsorNew":"Dyve Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Dyve Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fulcrum Therapeutics Announces Completion of Enrollment in Phase 2b Trial of Losmapimod in FSHD","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Losmapimod","moa":"Mapk\/p38 alpha","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fulcrum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Celavet","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celavet Inc. Plans Submission of Equine Tendinitis Study to FDA\u2019s Center for Veterinary Medicine ","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"OK100 stem cell","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Celavet","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Celavet \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Celavet \/ Not Applicable"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bone Therapeutics receives Clinical Trial Application (CTA) approval for next clinical studies of its two lead candidates","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II\/ Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Fast-acting analgesic","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Bone Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bone Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fulcrum Therapeutics Announces Complete Data from Phase 1 Trial with Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Losmapimod","moa":"Mapk\/p38 alpha","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fulcrum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UNITY Biotechnology Completes Enrollment in Phase 1b Study of UBX0101","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"UBX0101","moa":"MDM2\/p53 interaction","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Unity Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Seikagaku","sponsor":"Eisai","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"Diclofenac conjugated sodium hyaluronate","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Seikagaku","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Seikagaku \/ Eisai","highestDevelopmentStatusID":"10","companyTruncated":"Seikagaku \/ Eisai"},{"orgOrder":0,"company":"Ra Pharmaceuticals","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","amount":"$2,300.0 million","upfrontCash":"Undisclosed","newsHeadline":"UCB Completes the Acquisition of Ra Pharmaceuticals - to Deliver Differentiated Therapies to Patients","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Acquisition","leadProduct":"Zilucoplan Sodium","moa":"Completent C5","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Ra Pharmaceuticals","amount2":2.2999999999999998,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":2.2999999999999998,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ra Pharmaceuticals \/ UCB","highestDevelopmentStatusID":"10","companyTruncated":"Ra Pharmaceuticals \/ UCB"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"American Regent","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"American Regent, Inc. to Acquire a Daiichi Sankyo Affiliate API Manufacturing Facility","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Acquisition","leadProduct":"Polysulfated glycosaminoglycan","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Daiichi Sankyo \/ American Regent","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sankyo \/ American Regent"},{"orgOrder":0,"company":"InGeneron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Study Finds InGeneron's Regenerative Cell Therapy to Significantly Reduce Pain and Improve Shoulder Function","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Autologous adipose-derived regenerative cells","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"InGeneron","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"InGeneron \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"InGeneron \/ Not Applicable"},{"orgOrder":0,"company":"Epirium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Epirium Bio Receives FDA Orphan-Drug Designation for EB 002 for the Treatment of Duchenne and Becker Muscular Dystrophy","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Epicatechin","moa":"Mitochondrial biogenesis","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Epirium","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Epirium \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Epirium \/ Not Applicable"},{"orgOrder":0,"company":"Taisho Pharmaceutical","sponsor":"BioAge Labs","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioAge Signs Exclusive License Agreement with Taisho to Develop and Commercialize Taisho\u2019s Phase 1 HIF-PH Inhibitor to Treat Aging","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"BGE-117","moa":"HIF-PHI","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Taisho Pharmaceutical","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Taisho Pharmaceutical \/ BioAge Labs","highestDevelopmentStatusID":"6","companyTruncated":"Taisho Pharmaceutical \/ BioAge Labs"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 RELIEF Study of TNX-102 SL for Management of Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable"},{"orgOrder":0,"company":"OrthoTrophix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OrthoTrophix Presents More Evidence on TPX-100 for Disease Modification in Knee Osteoarthritis in a New Abstract Published in a Journal","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"TPX-100","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"OrthoTrophix","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"OrthoTrophix \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OrthoTrophix \/ Not Applicable"},{"orgOrder":0,"company":"Eden Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Subjects Dosed in JHL's Phase I Clinical Study of a Denosumab Biosimilar","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Denosumab","moa":"TNFSF11","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Eden Biologics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eden Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Eden Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bone Therapeutics Treats First Patients in Pivotal JTA-004 Phase III Knee Osteoarthritis Study","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Fast-acting analgesic","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Bone Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bone Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"TLC Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TLC Highlights Findings in Abstract Accepted at OARSI 2020 and Published in Osteoarthritis and Cartilage","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"TLC Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Steroid","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"TLC Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TLC Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virpax Completes Pre-IND Meeting with FDA on Epoladerm","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Diclofenac Epolamine","moa":"COX","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Virpax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Posted Results from Pharmacokinetic Analyses of TNX-102 SL and TNX-601 CR at ASCP 2020 Meeting","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fulcrum Therapeutics Announces Multiple Presentations at the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Platform","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Losmapimod","moa":"Mapk\/p38 alpha","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fulcrum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Samumed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samumed Announces Publication of Phase 2 Data on Lorecivivint, Now in Pivotal Trials for Knee Osteoarthritis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Lorecivivint","moa":"CLK","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Samumed","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Samumed \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Samumed \/ Not Applicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen Finds Over 80% Of Patients with Spasticity And Cervical Dystonia Treated With Botulinum Toxin-A Experience Symptom Recurrence","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Botulinum toxin type A","moa":"SNAP-25","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"RTW Investments","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Avidity Biosciences Completes $100 Million Series C Financing","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Series C Financing","leadProduct":"Antibody-Oligonucleotide Conjugates","moa":"DMPK","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Avidity Biosciences","amount2":0.10000000000000001,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Avidity Biosciences \/ RTW Investments","highestDevelopmentStatusID":"5","companyTruncated":"Avidity Biosciences \/ RTW Investments"},{"orgOrder":0,"company":"Harvard Stem Cell Institute","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Muscular Dystrophy Collaboration Aims to Correct Muscle Stem Cells\u2019 DNA","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"CRISPR\/Cas9 genome","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Discovery","graph3":"Harvard Stem Cell Institute","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Harvard Stem Cell Institute \/ Sarepta Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Harvard Stem Cell Institute \/ Sarepta Therapeutics"},{"orgOrder":0,"company":"Kolon TissueGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kolon Tissuegene Announces Plans To Resume US Phase III Clinical Trial For TG-C","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"TissueGene-C","moa":"Chondrocytes","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Kolon TissueGene","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Kolon TissueGene \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kolon TissueGene \/ Not Applicable"},{"orgOrder":0,"company":"Longeveron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longeveron Announces Japanese Approval of Clinical Trial for Treatment of Aging Frailty With Longeveron's Stem Cells","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Longeveron Mesenchymal Stem Cells","moa":"VEGF","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Longeveron","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Longeveron \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Bioiberica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Strategic Distribution Between Bayer Animal Health and Bioiberica in the International Companion Animal Health Market","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Chondroitin Sulfate Sodium","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Bayer AG \/ Bioiberica","highestDevelopmentStatusID":"12","companyTruncated":"Bayer AG \/ Bioiberica"},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sobi and Selecta Announce Strategic Licensing Agreement for SEL-212, a Phase 3-ready Novel Treatment for Chronic Refractory Gout","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Pegadricase","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Selecta Biosciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Selecta Biosciences \/ Sobi","highestDevelopmentStatusID":"8","companyTruncated":"Selecta Biosciences \/ Sobi"},{"orgOrder":0,"company":"Mithra Pharmaceuticals","sponsor":"Spirig Healthcare","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mithra Signs LSA for Commercialization of Tibelia\u00ae in Liechtenstein and Switzerland","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Tibolone","moa":"Sulphatase","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Mithra Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Hormone","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mithra Pharmaceuticals \/ Spirig Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"Mithra Pharmaceuticals \/ Spirig Healthcare"},{"orgOrder":0,"company":"Neurana Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurana Pharmaceuticals Announces First Patient Enrolled in CNS Effects Clinical Study","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tolperisone","moa":"NaV Channel","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Neurana Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurana Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurana Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amphastar Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Succinylcholine Chloride Injection USP, 200 mg\/10 mL (20 mg\/mL) Multiple-Dose Vial","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Succinylcholine Chloride","moa":"Muscle-type nicotinic acetylcholine receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Amphastar Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amphastar Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amphastar Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"SparingVision","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Pfenex Announces Enters New Partnership in Latin America, and Provides CRM197 Business Update","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2020","year":"2020","type":"Agreement","leadProduct":"Teriparatide","moa":"PTH receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"SparingVision","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"SparingVision \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"SparingVision \/ Undisclosed"},{"orgOrder":0,"company":"Pfenex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfenex Announces Positive European CHMP Opinion for PF708","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Pfenex","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfenex \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfenex \/ Not Applicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Exela Pharma Sciences, LLC.","pharmaFlowCategory":"D","amount":"$42.0 million","upfrontCash":"$14.5 million","newsHeadline":"Avadel Sells Sterile Injectables Portfolio; will Focus on Narcolepsy","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Divestment","leadProduct":"Neostigmine Methylsulfate","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Avadel Pharmaceuticals","amount2":0.040000000000000001,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Injection","sponsorNew":"Avadel Pharmaceuticals \/ Exela Sterile Medicines LLC","highestDevelopmentStatusID":"12","companyTruncated":"Avadel Pharmaceuticals \/ Exela Sterile Medicines LLC"},{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen Announces Updated Indication for Dysport\u00ae (abobotulinumtoxinA) for the Treatment of Spasticity in Children","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Botulinum toxin type A","moa":"SNAP-25","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ipsen \/ Not Applicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Completes Enrollment in Phase 3 RELIEF Trial of TNX-102 SL for Management of Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable"},{"orgOrder":0,"company":"Unichem Laboratories Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Unichem Lab Gets USFDA Nod for Baclofen Tablets; Stock Ends Higher","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Baclofen","moa":"GABA B receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Unichem Laboratories Limited","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Unichem Laboratories Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Unichem Laboratories Limited \/ Not Applicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entera Bio Ltd Provides Update on Phase 2 Clinical Trial of EB613 in Postmenopausal Women With Osteoporosis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Antares Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Commercial Product Using Antares Pharma\u2019s Multi-Dose Pen Platform Launches in Europe","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Antares Pharma","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Antares Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Antares Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"$100.0 million","newsHeadline":"Sobi And Selecta Announce Closing of Previously Announced Strategic Licensing Agreement For Sel-212","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Pegadricase","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Selecta Biosciences","amount2":0.10000000000000001,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Selecta Biosciences \/ Sobi","highestDevelopmentStatusID":"8","companyTruncated":"Selecta Biosciences \/ Sobi"},{"orgOrder":0,"company":"Mayne Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mayne Pharma Launches Chlorzoxazone Tablet in the United States","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Chlorzoxazone","moa":"Intermediate conductance calcium-activated potassium channel protein 4","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Mayne Pharma","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mayne Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mayne Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Dynacure","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dynacure Gets Rare Pediatric Disease Designation from U.S. FDA for DYN101 for Myotubular and Centronuclear Myopathies","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Dynamin 101","moa":"Dynamin 2 expression","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Dynacure","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Dynacure \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Dynacure \/ Not Applicable"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Keros Therapeutics, Inc. Announces Completion of Dosing of Planned Cohorts in KER-047 Phase 1 Trial and Provides Program Update","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"KER-047","moa":"Alk2","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Keros Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Keros Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Keros Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$1.1 million","upfrontCash":"Undisclosed","newsHeadline":"Bone Therapeutics Receives Eur 1.0 Million to Advance Ongoing JTA-004 Phase III Knee Osteoarthritis Study","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Funding","leadProduct":"Fast-acting Analgesic","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Bone Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Bone Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entera Bio Announces Management Changes","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fulcrum\u2019s losmapimod Fails Interim Analysis in Muscle Wasting Trial","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Losmapimod","moa":"Mapk\/p38 alpha","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fulcrum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Epirium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Epirium Bio Announces Commencement of Phase 1 Clinical Trial of EPM-01 in Becker Muscular Dystrophy","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Epicatechin","moa":"Mitochondrial biogenesis","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Epirium","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Epirium \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Epirium \/ Not Applicable"},{"orgOrder":0,"company":"Unity Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Unity Biotechnology Announces 12-Week Data From Ubx0101 Phase 2 Clinical Study In Patients With Painful Osteoarthritis Of The Knee","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"UBX0101","moa":"MDM2\/p53 interaction","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Unity Biotechnology","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Unity Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Unity Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Amzell B.V","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 2\/3 Trial Suggests that Amzell\u2019s New Topical Treatment (AMZ001) for the Treatment of Knee Osteoarthritis Symptoms Is Effective","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2020","year":"2020","type":"Not Applicable","leadProduct":"Diclofenac Sodium","moa":"COX","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"Amzell B.V","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Gel","sponsorNew":"Amzell B.V \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Amzell B.V \/ Not Applicable"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Fibromyalgia biotech Virios Therapeutics files for a $35 million IPO","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","year":"2020","type":"Public Offering","leadProduct":"IMC-1","moa":"HSV-1 DNA replication","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0.040000000000000001,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Virios Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Neurana Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurana Pharmaceuticals to Present Tolperisone Data at PAINWeek\u00ae National Conference","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Tolperisone","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Neurana Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Neurana Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurana Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Initiates Enrollment in Second Potentially Pivotal Phase 3 Study of TNX-102 SL for the Management of Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable"},{"orgOrder":0,"company":"Flexion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Flexion Therapeutics Announces Treatment of First Patient in Second Cohort of FX201 Phase 1 Dose-Escalation Trial","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Humantakinogene hadenovec","moa":"IL-1 receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Flexion Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Flexion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Flexion Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Radius Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Radius Health: Enrollment Completed for Phase 3 wearABLe Trial","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Abaloparatide Acetate","moa":"PTH1 receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Radius Health","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Trabsdermal Patch","sponsorNew":"Radius Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Radius Health \/ Not Applicable"},{"orgOrder":0,"company":"Haoma Medica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Haoma Medica to Present Scientific Data on NaQuinate, a Potential New Treatment for Osteoporosis, at ASBMR 2020 Annual Meeting","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"NaQuinate","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Haoma Medica","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Haoma Medica \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Haoma Medica \/ Not Applicable"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Keros Therapeutics Presents Results from Preclinical Studies Investigating KER-012 at ASBMR 2020","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"KER-012","moa":"ACVR2A","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Keros Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Keros Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Keros Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ponce De Leon Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Study Reveals Longevity Benefits of Calcium Alpha-Ketoglutarate in Scientific Journal Cell Metabolism","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Calcium Alpha-Ketoglutarate","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Ponce De Leon Health","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ponce De Leon Health \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ponce De Leon Health \/ Not Applicable"},{"orgOrder":0,"company":"Grunenthal","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gr\u00fcnenthal Closes a Deal with Teva to Market Teriparatide","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Teriparatide","moa":"PTH receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Grunenthal","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Grunenthal \/ Teva Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Grunenthal \/ Teva Pharmaceutical"},{"orgOrder":0,"company":"Histogen","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Histogen Announces $2M Grant Award from the Department of Defense for Clinical Advancement of HST-003 for Cartilage Regeneration in the Knee","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Funding","leadProduct":"HST-003","moa":"Hyaline cartilage","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Histogen","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Histogen \/ U.S. Department of Defense","highestDevelopmentStatusID":"7","companyTruncated":"Histogen \/ U.S. Department of Defense"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Virios Therapeutics Sets Terms for $30 million IPO","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Public Offering","leadProduct":"IMC-1","moa":"HSV-1 DNA replication","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Virios Therapeutics \/ ThinkEquity","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ ThinkEquity"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Selecta Biosciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Randomized in Sobi's Phase 3 DISSOLVE Clinical Program of SEL-212 for Chronic Refractory Gout","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Pegadricase","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Selecta Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Selecta Biosciences"},{"orgOrder":0,"company":"Aptinyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptinyx Recommences Patient Recruitment in Phase 2 Study of NYX-2925 in Patients with Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"NYX-2925","moa":"NMDA receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aptinyx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ Not Applicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Plans to Complete Phase 3 RELIEF Study of TNX-102 SL to Manage Fibromyalgia Based on Results of Interim Analysis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"JPMorgan Chase Bank","pharmaFlowCategory":"D","amount":"$160.0 million","upfrontCash":"Undisclosed","newsHeadline":"Eagle Pharmaceuticals Commences $25 Million Accelerated Share Repurchase as Part of Existing $160 Million Share Repurchase Program","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Financing","leadProduct":"Dantrolene","moa":"RYR1","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Eagle Pharmaceuticals","amount2":0.16,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.16,"dosageForm":"Intranasal","sponsorNew":"Eagle Pharmaceuticals \/ JPMorgan Chase Bank","highestDevelopmentStatusID":"12","companyTruncated":"Eagle Pharmaceuticals \/ JPMorgan Chase Bank"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Releases Positive Results of Phase 1B Trial of Resiniferatoxin (RTX) In Reduction of OsteoArthritis (OA) Knee Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Resiniferatoxin","moa":"TRPV1","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Epidural Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$526.7 million","upfrontCash":"$58.6 million","newsHeadline":"Merck Announces Out-Licensing Agreement for Phase II-ready Anti-ADAMTS5 Nanobody for Osteoarthritis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"M6495","moa":"ADAMTS5","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Merck & Co","amount2":0.53000000000000003,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.53000000000000003,"dosageForm":"Subcutaneous Injection","sponsorNew":"Merck & Co \/ Novartis","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Novartis"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fulcrum Therapeutics Announces Multiple Presentations During the Virtual 25th International Congress of the World Muscle Society","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Losmapimod","moa":"Mapk\/p38 alpha","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fulcrum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bone Therapeutics Reaches 50% Treated Patients in Ongoing JTA-004 Phase III Pivotal Knee Osteoarthritis Study","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Fast-acting Analgesic","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Bone Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bone Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nexus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nexus Pharmaceuticals Receives FDA Approval for Succinylcholine Chloride Injection, USP","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Succinylcholine Chloride","moa":"Muscle-type nicotinic acetylcholine receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Nexus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nexus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Nexus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entera Bio Ltd Announces Completion of Enrollment In Phase 2 Clinical Trial of Eb613 In Osteoporosis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Shanghai Henlius Biotech First Patient Dosed in Phase 1 Clinical Trial of Henlius Denosumab Biosimilar HLX14","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Denosumab","moa":"TNFSF11","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Shanghai Henlius Biotech","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Henlius Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Succinylcholine Chloride Injection USP, 200 mg\/10 mL (20 mg\/mL) in the U.S. Market","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Succinylcholine Chloride","moa":"Muscle-type nicotinic acetylcholine receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Dr. Reddy\\\\\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dr. Reddy\\\\\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\\\\\'s Laboratories \/ Not Applicable"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samsung Bioepis Initiates Phase 1 Clinical Trial for SB16, Proposed Biosimilar to Prolia (Denosumab)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Denosumab","moa":"TNFSF11","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Samsung Bioepis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bioepis \/ Not Applicable"},{"orgOrder":0,"company":"3S Bio Inc","sponsor":"Selecta Biosciences","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"3SBio Inc. Received Milestone Payment of USD 4 Million Upon Commencement of Phase III Clinical Program of SEL-212","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Pegadricase","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"3S Bio Inc","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"3S Bio Inc \/ Selecta Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"3S Bio Inc \/ Selecta Biosciences"},{"orgOrder":0,"company":"Neurana Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurana Pharmaceuticals Announces Publication in the Journal of Pain Research","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Tolperisone","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Neurana Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurana Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurana Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Haoma Medica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Haoma Medica Completes First-in-Human Trial for NaQuinate","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"NaQuinate","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Haoma Medica","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Haoma Medica \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Haoma Medica \/ Not Applicable"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$69.0 million","upfrontCash":"Undisclosed","newsHeadline":"Rani Therapeutics Raises $69 Million Series E To Advance Clinical Trials And Manufacturing Of Robotic Pill","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2020","year":"2020","type":"Series E Financing","leadProduct":"Teriparatide","moa":"PTH 34 N-terminal amino acid","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0.070000000000000007,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.070000000000000007,"dosageForm":"Enteric-coated Capsule","sponsorNew":"Rani Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Rani Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"Berg Health","sponsor":"AdventHealth","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BERG Deepens Research Collaboration With AdventHealth To Advance Aging, Metabolism and Nash Research","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Collaboration","leadProduct":"Ubidecarenone","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Berg Health","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Oral Nanosuspension","sponsorNew":"Berg Health \/ AdventHealth","highestDevelopmentStatusID":"8","companyTruncated":"Berg Health \/ AdventHealth"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Samsung Bioepis Initiates Phase 3 Clinical Trial for SB16, Proposed Biosimilar to Prolia (Denosumab)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Denosumab","moa":"TNFSF11","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Samsung Bioepis","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Samsung Bioepis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Samsung Bioepis \/ Not Applicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Healthcare Royalty Management","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$200.0 million","newsHeadline":"Regenxbio Announces Agreement to Monetize Portion of Zolgensma\u00ae Royalties for $200 Million","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Cell and Gene therapy","productStatus":"Approved","date":"December 2020","year":"2020","type":"Agreement","leadProduct":"Onasemnogene abeparvovec-xioi","moa":"SMN2 splicing","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Regenxbio","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regenxbio \/ Healthcare Royalty Management","highestDevelopmentStatusID":"12","companyTruncated":"Regenxbio \/ Healthcare Royalty Management"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai's Osteoporosis Agent Edirol Obtains Regulatory Approval in China","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Eldecalcitol","moa":"Vitamin D3 receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Oral","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bone Therapeutics Completes Recruitment and Patient Treatment in JTA-004 Pivotal Phase III Knee Osteoarthritis Study","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Fast-acting Analgesic","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Bone Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bone Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Launches Meloxicam Capsules","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Meloxicam","moa":"COX-2","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Virios Therapeutics Announces Pricing of Initial Public Offering","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2020","year":"2020","type":"Public Offering","leadProduct":"Famciclovir","moa":"HSV-1 DNA replication","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"","sponsorNew":"Virios Therapeutics \/ ThinkEquity","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ ThinkEquity"},{"orgOrder":0,"company":"PALADIN LABS","sponsor":"Endo International","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Endo Announces Licensing Agreement for Paladin Labs Inc. to Commercialize Abaloparatide in Canada","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"January 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Abaloparatide Acetate","moa":"PTH1 receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"PALADIN LABS","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"PALADIN LABS \/ Endo International","highestDevelopmentStatusID":"10","companyTruncated":"PALADIN LABS \/ Endo International"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bone Therapeutics Treats First Patient in ALLOB Phase IIb Tibial Fracture Study","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Allogeneic Osteoblastic Cells","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"Bone Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Unichem Laboratories Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Celecoxib","moa":"COX-2","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Unichem Laboratories Limited","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Unichem Laboratories Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Unichem Laboratories Limited \/ Not Applicable"},{"orgOrder":0,"company":"Organogenesis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Organogenesis Enrolls First Patient in Pivotal Phase 3 Clinical Trial of RMAT-Designated ReNu\u00ae for Knee Osteoarthritis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Amniotic suspension allograft","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Organogenesis","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Organogenesis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Organogenesis \/ Not Applicable"},{"orgOrder":0,"company":"Taisho Pharmaceutical","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chugai Pharma, Taisho Pharma Terminate Co-Marketing Agreement for Edirol to Treat Osteoporosis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Termination","leadProduct":"Eldecalcitol","moa":"Vitamin D3 receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Taisho Pharmaceutical","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Taisho Pharmaceutical \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Taisho Pharmaceutical \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Xalud Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xalud Therapeutics Appoints Diem Nguyen, Ph.D., as Chief Executive Officer","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"XT-150","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"Xalud Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Xalud Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Xalud Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Theramex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Theramex Launches Livogiva\u00ae, a New Teriparatide Pre-Filled Pen for the Treatment of Severe Osteoporosis London","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Biosimilar","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Theramex","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Solution for Injection in Pre-filled Pen","sponsorNew":"Theramex \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Theramex \/ Not Applicable"},{"orgOrder":0,"company":"Signature Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Signature Cord Prime\u2122 Receives IND Approval from FDA for Phase 1 Study in Patients with Symptomatic Osteoarthritis of the Knee.","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Micronized umbilical cord tissue","moa":"Cell growth","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Signature Biologics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Signature Biologics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Signature Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Flexion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Flexion Therapeutics to Advance Investigational Gene Therapy FX201 into High Dose Cohort of Phase 1 Clinical Trial in Knee Osteoarthritis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Humantakinogene hadenovec","moa":"IL-1 receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Flexion Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Flexion Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Flexion Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aardvark Therapeutics","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sorrento Therapeutics and Scilex Holding Ink Agreement with Aardvark Therapeutics to Acquire Its ARD-301","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Naltrexone","moa":"Mu\/kappa\/delta opioid receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Aardvark Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Aardvark Therapeutics \/ Sorrento Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Aardvark Therapeutics \/ Sorrento Therapeutics"},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"Virpax Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Virpax to Initiate Investigational New Drug (IND) Enabling Studies for Epoladerm(TM)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Agreement","leadProduct":"Diclofenac Epolamine","moa":"COX-1","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Charles River Laboratories, Inc","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"metered-dose spray film","sponsorNew":"Charles River Laboratories, Inc \/ Virpax","highestDevelopmentStatusID":"4","companyTruncated":"Charles River Laboratories, Inc \/ Virpax"},{"orgOrder":0,"company":"Bioventus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bioventus Reports First Patients Enrolled in Phase 1 Clinical Trial of MOTYS\u2122 (PTP-001) for the Treatment of Knee OA","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"PTP-001","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Bioventus","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Bioventus \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bioventus \/ Not Applicable"},{"orgOrder":0,"company":"Amplicore","sponsor":"Photon Fund","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Amplicore, Inc. Announces Closing of a Successful $4M Seed Funding Round","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Financing","leadProduct":"AM3101","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Amplicore","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amplicore \/ Photon Fund","highestDevelopmentStatusID":"4","companyTruncated":"Amplicore \/ Photon Fund"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Veristat","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antibe Therapeutics Receives FDA Clearance of IND Application for Otenaproxesul for Osteoarthritis Pain","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Not Applicable","leadProduct":"Otenaproxesul","moa":"COX2","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Antibe Therapeutics \/ Veristat","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Veristat"},{"orgOrder":0,"company":"Biosplice","sponsor":"Samil Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biosplice Licenses Rights to Lorecivivint, a Novel Phase 3 Osteoarthritis Drug Candidate, to Samil for the Republic of Korea","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Lorecivivint","moa":"CLK2","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Biosplice","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Biosplice \/ Samil Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Biosplice \/ Samil Pharmaceutical"},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ZYUS Launches HOPE (Human Osteoarthritis Pain Evaluation) Phase 1 First in Human Clinical Trials","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Trichomylin","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"ZYUS Life Sciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"ZYUS Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ZYUS Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Biosplice","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biosplice Publishes Successful Clinical Trial in Knee Osteoarthritis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Lorecivivint","moa":"CLK","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Biosplice","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Biosplice \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biosplice \/ Not Applicable"},{"orgOrder":0,"company":"AKL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data Presented by AKL Research and Development Advances Understanding of Biological Effects of APPA to Protect Against Joint Damage","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"AKL4","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"AKL Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AKL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AKL Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virios Therapeutics to Present at the Benzinga Global Small Cap Conference","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"IMC-1","moa":"HSV-1 DNA replication","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Virios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"NattoPharma","sponsor":"Gnosis by Lesaffre","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gnosis by Lesaffre Enhances Vitamin K2 Offering with Acquisition of NattoPharma","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Acquisition","leadProduct":"Vitamin K2","moa":"SXR","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"NattoPharma","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"NattoPharma \/ Gnosis","highestDevelopmentStatusID":"12","companyTruncated":"NattoPharma \/ Gnosis"},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Aureuspharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ZYUS Life Sciences Partners with Portugal\u2019s Aureuspharma to Further Increase International Patient Access to Medical Cannabinoids","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Partnership","leadProduct":"Trichomylin","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"ZYUS Life Sciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"ZYUS Life Sciences \/ Aureuspharma","highestDevelopmentStatusID":"6","companyTruncated":"ZYUS Life Sciences \/ Aureuspharma"},{"orgOrder":0,"company":"Xalud Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xalud Therapeutics\u2019 XT-150, Achieves Multiple Clinical Milestones in Pathologic Inflammation and Neuroimmunology Therapeutic Areas","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"XT-150","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"Xalud Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable Solution","sponsorNew":"Xalud Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Xalud Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Bioventus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bioventus Study Shows Novel Placental Tissue Biologic Candidate Inhibited Inflammatory and Catabolic Responses In Vitro","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"PTP-001","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Bioventus","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Bioventus \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Bioventus \/ Not Applicable"},{"orgOrder":0,"company":"AKL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AKL's Investigational Osteoarthritis Drug APPA Reduces Senescence and Reactive Oxygen Species Production","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"CAS 498-02-2","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"AKL Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"AKL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AKL Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virios Therapeutics Presents Phase 2a Fibromyalgia Trial Data on Efficacy Analyses of Key Secondary Endpoints","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"IMC-1","moa":"HSV-1 DNA replication","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Virios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virios Therapeutics Highlights Safety Data from Phase 2a Fibromyalgia Trial at IASP World Congress","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"IMC-1","moa":"HSV-1 DNA replication","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Virios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Aggrega Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Breckenridge Signs Multi-Product Agreement With Aggrega Pharma LLC","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Agreement","leadProduct":"Succinylcholine Chloride","moa":"Ach receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Breckenridge Pharmaceutical","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Breckenridge Pharmaceutical \/ Aggrega Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Breckenridge Pharmaceutical \/ Aggrega Pharma"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Horizon Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arrowhead and Horizon Collaborate to Develop RNAi Therapeutic","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"ARO-XDH","moa":"Xanthine dehydrogenase","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arrowhead Pharmaceuticals \/ Horizon Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Arrowhead Pharmaceuticals \/ Horizon Therapeutics"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entera Bio Receives Foundational Patent for its Oral PTH using its Platform Oral Protein Delivery Technology in European Union","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Biophytis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Results of Biophytis SARA-INT Phase 2 Trial with Sarconeos (BIO101) in Sarcopenia will be Released by August 2021","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Sarconeos","moa":"MAS receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biophytis","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biophytis \/ Not Applicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entera Bio to Conduct Conference Call on June 30 to Discuss Phase 2 Results for EB613","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axsome Therapeutics to Submit NDA to US FDA for AXS-14 for Management of Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Esreboxetine Succinate","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fulcrum Therapeutics Announces Results from ReDUX4 Trial with Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Not Applicable","leadProduct":"Losmapimod","moa":"p38-alpha\/beta-Mapk","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fulcrum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"European Investment Bank","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bone Therapeutics Secures Up to \u20ac16 Million Loan Financing from the European Investment Bank","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Financing","leadProduct":"Fast-acting Analgesic","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Bone Therapeutics \/ European Investment Bank","highestDevelopmentStatusID":"10","companyTruncated":"Bone Therapeutics \/ European Investment Bank"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Clears Sorrento Phase 2 Trial Of Non-Opioid Product Candidate Resiniferatoxin For Treatment of the Knee Pain in Osteoarthritis Patients","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Resiniferatoxin","moa":"TRPV1","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bone Therapeutics Provides Update on the Progress of Clinical Studies","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"JTA-004","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Bone Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Bone Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Bone Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Abbott Gets CDSCO Approval for Marketing of Estradiol, Dydrogesterone FDC","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Estradiol","moa":"Estrogen receptor alpha","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Abbott Laboratories","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Hormone","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Abbott Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Abbott Laboratories \/ Not Applicable"},{"orgOrder":0,"company":"The Valens Company","sponsor":"Harvest One Cannabis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"The Valens Agreement Manufacture and Distribute Leading Infused Topical Brand","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Agreement","leadProduct":"Capsaicin","moa":"TRPV1","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"The Valens Company","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"The Valens Company \/ Harvest One Cannabis","highestDevelopmentStatusID":"12","companyTruncated":"The Valens Company \/ Harvest One Cannabis"},{"orgOrder":0,"company":"Biosplice","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biosplice Phase 2B Lorecivivint Clinically Meaningful to Knee Osteoarthritis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Lorecivivint","moa":"CLK","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Biosplice","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intraarticular Injection","sponsorNew":"Biosplice \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Biosplice \/ Not Applicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Interim Analysis of Phase 3 of TNX-102 SL the Management of Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virios' Clinical Sites Gets Fully Operational in Phase 2b Fibromyalgia Study Featuring FDA \u201cFast Track\u201d Review Designated for Oral IMC-1","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Famciclovir","moa":"HSV-1 DNA replication","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Virios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antibe Therapeutics Provides Clinical Update for Otenaproxesul","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Otenaproxesul","moa":"COX2","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Antibe Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Xalud Therapeutics","sponsor":"PBM Capital","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Xalud Therapeutics Completes Oversubscribed $30 Million Series C Financing","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Series C Financing","leadProduct":"XT-150","moa":"IL-10v","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Xalud Therapeutics","amount2":0.029999999999999999,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Intrathecal Injection","sponsorNew":"Xalud Therapeutics \/ PBM Capital","highestDevelopmentStatusID":"8","companyTruncated":"Xalud Therapeutics \/ PBM Capital"},{"orgOrder":0,"company":"Persica Pharmaceuticals","sponsor":"Micron Research Ltd","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Persica Pharmaceuticals has Completed the First Stage of Its Clinical Trial on Unique Injectable PP353, To Treat Chronic Lower Back Pain","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"PP353","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Persica Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Persica Pharmaceuticals \/ Micron Research Ltd","highestDevelopmentStatusID":"7","companyTruncated":"Persica Pharmaceuticals \/ Micron Research Ltd"},{"orgOrder":0,"company":"Neurana Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurana Pharmaceuticals to Present at Napa Pain Conference and PAIN Week","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Tolperisone","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Neurana Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Neurana Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurana Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virios Therapeutics Granted New Patent for Antiviral Inhibitor Combination","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Famciclovir","moa":"HSV-1 DNA replication","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Virios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Grants Fast Track Designation to Novartis\u2019 LNA043 for Treatment for Osteoarthritis of the Knee","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Canakinumab","moa":"ANGPTL3","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intra-Articular Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Remedium","sponsor":"Tufts University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Remedium Bio Announces Research Agreement with a Leading Rheumatology Laboratory","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Agreement","leadProduct":"RMD 1101","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Remedium","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Remedium \/ Tufts University","highestDevelopmentStatusID":"4","companyTruncated":"Remedium \/ Tufts University"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Celltrion","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Celltrion Healthcare and 180 Life Sciences Enter Into Memorandum of Understanding for a Supply Agreement for the Ongoing Supply of Drug for Anti-TNF Product Trials for Novel Indications","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2021","year":"2021","type":"Agreement","leadProduct":"Infliximab","moa":"TNF alpha","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"180 Life Sciences \/ Celltrion Healthcare","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Celltrion Healthcare"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Virpax \u00ae Pharmaceuticals Announces Closing of a $ 40 Million Public Offering of Common Stock","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Public Offering","leadProduct":"Diclofenac","moa":"COX","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0.040000000000000001,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"Topical Spray Film","sponsorNew":"Virpax Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"HemoShear Therapeutics","sponsor":"Horizon Therapeutics","pharmaFlowCategory":"D","amount":"$500.0 million","upfrontCash":"Undisclosed","newsHeadline":"HemoShear Therapeutics Advancing Several Novel Compounds for Horizon Therapeutics plc Gout Discovery Pipeline","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"September 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"HemoShear Therapeutics","amount2":0.5,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.5,"dosageForm":"","sponsorNew":"HemoShear Therapeutics \/ Horizon Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"HemoShear Therapeutics \/ Horizon Therapeutics"},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eupraxia Pharmaceuticals Inc. Provides Update for Phase 2 Osteoarthritis Drug Candidate EP-104IAR","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Eupraxia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Steroid","amount2New":0,"dosageForm":"Intra-articular Injection","sponsorNew":"Eupraxia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eupraxia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Allena Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allena Pharmaceuticals Commences Dosing of Gout Patients in Second Phase 2a Trial of ALLN-346","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Engineered Urate Oxidase","moa":"Urate","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Allena Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allena Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Allena Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Biophytis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biophytis to Present Full Results From the SARA-INT Phase 2b Trial of Sarconeos (BIO101) in Sarcopenia at the 11th Annual International Conference on Frailty and Sarcopenia Research (ICFSR) September 29 \u2013 October 2, 2021","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Sarconeos","moa":"MAS receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biophytis","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biophytis \/ Not Applicable"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leading Next Wave of Psychedelic Drug Development","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Tryp Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Tryp Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tryp Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Biosplice","sponsor":"Haisco Pharmaceutical","pharmaFlowCategory":"D","amount":"$140.0 million","upfrontCash":"$20.0 million","newsHeadline":"Biosplice Licenses Development and Commercialization Rights for Lorecivivint, a Novel Phase 3 Osteoarthritis Drug Candidate, to Haisco","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Lorecivivint","moa":"CLK","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Biosplice","amount2":0.14000000000000001,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0.14000000000000001,"dosageForm":"Intrarticular Injection","sponsorNew":"Biosplice \/ Haisco Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Biosplice \/ Haisco Pharmaceutical"},{"orgOrder":0,"company":"Cintex","sponsor":"Senores Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cintex Services, LLC and Senores Pharmaceuticals, Inc. Launch Chlorzoxazone Tablets USP, 250 mg in the U.S. Market","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Chlorzoxazone","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Cintex","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cintex \/ Senores Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Cintex \/ Senores Pharmaceuticals"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entera Bio Presents Positive Phase 2 6-Month Bone Mineral Density Data for Oral PTH Formulation at Late Breaker ASBMR Conference Session","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio Ltd \/ Not Applicable"},{"orgOrder":0,"company":"GLAND PHARMA LIMITED","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gland Pharma Receives Tentative Approval for Sugammadex Injection","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Sugammadex Sodium","moa":"Sugammadex?rocuronium chelating complex","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"GLAND PHARMA LIMITED","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GLAND PHARMA LIMITED \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GLAND PHARMA LIMITED \/ Not Applicable"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actimed Therapeutics Continues to Strengthen Intellectual Property Portfolio with Newly Granted US and Canadian Patents","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Pindolol","moa":"Beta-1 receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Actimed Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Actimed Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Actimed Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Faraday Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Faraday Pharmaceuticals Announces First Patient Enrolled in Phase 2 Study for ICU-Acquired Weakness","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Sodium Iodide","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Faraday Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Faraday Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Faraday Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Completion of Enrollment in Phase III Comparative Study for Investigational Regenerative Cellular Medicine (gMSC\u00ae1) for Knee Chondrogenesis Using Allogeneic 3D Artificial Tissue of MSC","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Engineered Gingival Mesenchymal Stem Cells","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entera Bio Publishes Key Study Describing its Oral Delivery Technology Platform for Biologic Drugs","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Oxford Finance LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oxford Finance Provides $50 Million Credit Facility to Kezar Life Sciences, Inc.","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Financing","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Oxford Finance LLC","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Oxford Finance LLC"},{"orgOrder":0,"company":"MiMedx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Two New Studies Demonstrate In Vitro Bioactivity Potential of Micronized Dehydrated Human Amnion Chorion Membrane (mdHACM) to Prevent Pathological Processes Underlying Osteoarthritis (OA) and Tendinopathy","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Micronized Dehydrated Human Amnion Chorion Membrane","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"MiMedx","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"MiMedx \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"MiMedx \/ Not Applicable"},{"orgOrder":0,"company":"Allena Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Allena Pharmaceuticals Receives Fast Track Designation from FDA for the Development of ALLN-346 for Chronic Treatment of Hyperuricemia in Patients With Gout and Advanced Chronic Kidney Disease","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Engineered Urate Oxidase","moa":"Urate","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Allena Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Allena Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Allena Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Presents Positive Results from Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia at the American College of Rheumatology Convergence 2021","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable"},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pluristem Completes Enrollment of Its Multinational Phase III Study of Muscle Regeneration Following Hip Fracture Surgery","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"PLX-PAD","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Pluri","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pluri \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pluri \/ Not Applicable"},{"orgOrder":0,"company":"Delpor","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$2.5 million","upfrontCash":"Undisclosed","newsHeadline":"Delpor Advances Pipeline to Include Spasticity Maintenance Therapy with $2.5 Million NIH Grant for Tizanidine Implant","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Funding","leadProduct":"Tizanidine HCl","moa":"Adrenergic receptor alpha-2","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Delpor","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Delpor \/ NIH","highestDevelopmentStatusID":"1","companyTruncated":"Delpor \/ NIH"},{"orgOrder":0,"company":"Neurana Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurana Pharmaceuticals Completes Patient Enrollment in Phase 3 RESUME-1 Study","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Tolperisone","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Neurana Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurana Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurana Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$3.7 million","upfrontCash":"Undisclosed","newsHeadline":"Bone Therapeutics Successfully Raises EUR 3.3 Million in Private Placement","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Private Placement","leadProduct":"Allogeneic Osteoblastic Cells","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Bone Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"Bone Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bone Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Richter and Hikma Sign Exclusive Commercialisation and License Agreement for Denosumab in the US, a Proposed Biosimilar Referencing Prolia\u00ae and Xgeva\u00ae","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Denosumab","moa":"RANK","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Gedeon Richter","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gedeon Richter \/ Hikma","highestDevelopmentStatusID":"10","companyTruncated":"Gedeon Richter \/ Hikma"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"180 Life Sciences Corp.Co-Founder Prof. Jagdeep Nanchahal Presents Keynote Address at the 2021 International Dupuytren Symposium, Including Top Line Data From the Phase 2b Clinical Trial","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intra-Nodular Injection","sponsorNew":"180 Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virios Therapeutics Achieves Over 50% Enrollment Milestone in its Phase 2b Clinical Trial for Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"IMC-1","moa":"HSV-1 activation\/HSV-1 replication","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Virios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tryp Therapeutics Receives Confirmation from FDA to Proceed with Phase 2a Study in Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tryp Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"180 Life Sciences Provides Follow-Up Information on Oxford University and the Company\u2019s Successful Dupuytren\u2019s Phase 2b Clinical Trial Results","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intra-Nodular Injection","sponsorNew":"180 Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Begins Enrollment in Phase 2 Trial of Resiniferatoxin (RTX) for the Treatment of Pain Due to Knee Osteoarthritis (OA)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Resiniferatoxin","moa":"TRPV1","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intra Articular Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Radius Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Radius Announces Results from the wearABLe Trial Evaluating Abaloparatide Transdermal System in Postmenopausal Women with Osteoporosis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Abaloparatide Acetate","moa":"PTH receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Radius Health","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Radius Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Radius Health \/ Not Applicable"},{"orgOrder":0,"company":"Tremeau Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tremeau Pharmaceuticals ASH 2021 Presentations Highlight Unmet Need for Non-Opioid Pain Treatments for Patients with Bleeding Disorders","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"Rofecoxib","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tremeau Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tremeau Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tremeau Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Kolon TissueGene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kolon TissueGene To Expand Indications For TG-C","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"TissueGene-C","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Kolon TissueGene","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intra Articular Injection","sponsorNew":"Kolon TissueGene \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Kolon TissueGene \/ Not Applicable"},{"orgOrder":0,"company":"Xalud Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Xalud Therapeutics Receives FDA Fast Track Designation for XT-150 for the Treatment of Pain Associated with Osteoarthritis of the Knee","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2021","year":"2021","type":"Not Applicable","leadProduct":"XT-150","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"Xalud Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Index Knee Injection","sponsorNew":"Xalud Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Xalud Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Saol therapeutics","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amneal Acquires Saol Therapeutics\u2019 Baclofen Franchise","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Acquisition","leadProduct":"Baclofen","moa":"GABA B receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Saol therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Saol therapeutics \/ Amneal Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Saol therapeutics \/ Amneal Pharmaceuticals"},{"orgOrder":0,"company":"Altasciences Company Inc","sponsor":"Virpax Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altasciences Chosen by Virpax Pharmaceuticals, Inc. to Conduct First-in-Human Study of Epoladerm\u2122 for Chronic Pain Associated with Osteoarthritis of the Knee","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Diclofenac Epolamine","moa":"COX-1","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Altasciences Company Inc","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Topical Spray Film","sponsorNew":"Altasciences Company Inc \/ Virpax Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Altasciences Company Inc \/ Virpax Pharmaceuticals"},{"orgOrder":0,"company":"Medis","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lupin Signs Distribution Agreement with Medis for Orphan Drug NaMuscla\u00ae","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Agreement","leadProduct":"Mexiletine","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Medis","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medis \/ Lupin","highestDevelopmentStatusID":"12","companyTruncated":"Medis \/ Lupin"},{"orgOrder":0,"company":"BriOri BioTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriOri BioTech Inc. Granted Patent for Topical Formulation of Rofecoxib","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"Rofecoxib","moa":"COX-2","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"BriOri BioTech","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical","sponsorNew":"BriOri BioTech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BriOri BioTech \/ Not Applicable"},{"orgOrder":0,"company":"Oncocross","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncocross Launches Global Clinical Trials for AI-based Sarcopenia Treatment","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"OC514","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Oncocross","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oncocross \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncocross \/ Not Applicable"},{"orgOrder":0,"company":"Aptinyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","year":"2022","type":"Not Applicable","leadProduct":"NYX-2925","moa":"NMDA receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aptinyx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ Not Applicable"},{"orgOrder":0,"company":"Q BioMed","sponsor":"Chengdu Syncor Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Q BioMed Announces Initial $500k Order of Strontium89 to Chinese Market","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Agreement","leadProduct":"Strontium-89 Chloride","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Q BioMed","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Radiolabelled Compound","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Q BioMed \/ Chengdu Syncor Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Q BioMed \/ Chengdu Syncor Pharmaceutical"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fulcrum Therapeutics\u00ae Announces REACH, a Phase 3 Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Losmapimod","moa":"p38-alpha\/beta-Mapk","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fulcrum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virios Therapeutics to Present at the 34th Annual Roth Conference on Monday, March 14, 2022","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Famciclovir","moa":"HSV-1 DNA replication","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Virios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BriOri BioTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BriOri BioTech Inc. Granted Patent for Topical Formulation of Vioxx","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Rofecoxib","moa":"COX-2","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"BriOri BioTech","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"BriOri BioTech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BriOri BioTech \/ Not Applicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Vickers Vantage Corp","pharmaFlowCategory":"D","amount":"$1,640.0 million","upfrontCash":"Undisclosed","newsHeadline":"Scilex Holding Company, a Majority-Owned Subsidiary of Sorrento Therapeutics, Inc., to Become Publicly Traded Through a Merger With Vickers Vantage Corp. I","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Merger","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Scilex Pharmaceuticals","amount2":1.6399999999999999,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Steroid","amount2New":1.6399999999999999,"dosageForm":"Prefilled Syringe For Epidural","sponsorNew":"Scilex Pharmaceuticals \/ Vickers Vantage Corp","highestDevelopmentStatusID":"10","companyTruncated":"Scilex Pharmaceuticals \/ Vickers Vantage Corp"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Launches New Phase III Study to Reconcile Mixed Fibromyalgia Data","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"Adrenergic receptor alpha-1","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Sorrento Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Final Results for SP-102 (SEMDEXA\u2122) Efficacy and Safety from its Pivotal Phase 3 Clinical Trial Program for Sciatica Pain Management Supporting the Potential for","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Scilex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Steroid","amount2New":0,"dosageForm":"Prefilled Syringe For Epidural","sponsorNew":"Scilex Pharmaceuticals \/ Sorrento Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Scilex Pharmaceuticals \/ Sorrento Therapeutics"},{"orgOrder":0,"company":"Neurana Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurana Pharmaceuticals Seeks Strategic Alternatives Following Phase 3 Study","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Tolperisone","moa":"NaV Channel","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Neurana Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurana Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Neurana Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announces Phase 3 RALLY Study Results for TNX-102 SL 5.6 mg for the Management of Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"5-HT2C receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rani Therapeutics Announces Initiation of Phase 1 Study of RT-102 Oral PTH for Osteoporosis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH 34 N-terminal amino acid","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rani Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rani Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz, Inc. Issues Nationwide Recall of 13 Lots of Orphenadrine Citrate 100 mg Extended Release Tablets Due to Presence of a Nitrosamine Impurity","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Orphenadrine","moa":"H1 receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Sandoz B2B","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Extended Release Tablet","sponsorNew":"Sandoz B2B \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sandoz B2B \/ Not Applicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New UCB Data Analysis Adds to Demonstrated Efficacy of Romosozumab to Reduce the Risk of Fractures","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Romosozumab","moa":"Sclerostin","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma S.A \/ Not Applicable"},{"orgOrder":0,"company":"Propella Therapeutics","sponsor":"Aosaikang Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Propella Therapeutics Announces Licensing Agreement with Jiangsu Aosaikang Pharmaceutical Co. Ltd. (ASK Pharm) for Development and Commercial Rights to CGS-200-5 in Greater China","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Capsaicin","moa":"TRPV1","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Propella Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Propella Therapeutics \/ Aosaikang Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Propella Therapeutics \/ Aosaikang Pharmaceutical"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fulcrum Therapeutics Announces Multiple Presentations on FSHD at the American Academy of Neurology's Annual Meeting","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Losmapimod","moa":"p38-alpha\/beta-Mapk","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fulcrum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Initiates Enrollment in the RESILIENT Study, a Potentially Pivotal Phase 3 Study of TNX-102 SL for the Management of Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"Adrenergic receptor alpha-1","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virpax Completes All FDA-Required Pre-Clinical Studies for Epoladerm","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Diclofenac Epolamine","moa":"COX1\/COX2","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Virpax Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Longeveron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longeveron to Present at Longevity Leaders World Congress; Latinos and Alzheimer's Symposium; International Frailty and Sarcopenia Research Conference","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Lomecel-B","moa":"IL-10","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Longeveron","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Longeveron \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Longeveron \/ Not Applicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioRestorative Therapies Announces Selection of 10 Clinical Sites for its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"BRTX-100","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Biorestorative Therapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Not Applicable"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioAge Announces First Cohort Dosed in Phase 1b Clinical Trial of the Apelin Receptor Agonist BGE-105, Under Development for Muscle Aging Indications","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"BGE-105","moa":"Apelin receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"BioAge Labs","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BioAge Labs \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioAge Labs \/ Not Applicable"},{"orgOrder":0,"company":"SpineThera","sponsor":"Department of Defense","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"SpineThera Awarded $5 Million Grant from Department of Defense","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Funding","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"SpineThera","amount2":0.01,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.01,"dosageForm":"Epidural Injection","sponsorNew":"SpineThera \/ Department of Defense","highestDevelopmentStatusID":"7","companyTruncated":"SpineThera \/ Department of Defense"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virios Therapeutics Completes Enrollment of 425 Patients in Phase 2b \u201cFORTRESS\u201d Clinical Trial for Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Famciclovir","moa":"HSV-1 DNA replication","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Virios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transcenta Announces First Patient Dosed in China Study of Anti-sclerostin Monoclonal Antibody TST002 for the Treatment of Osteoporosis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Blosozumab","moa":"Sclerostin","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Transcenta Holding \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta Holding \/ Eli Lilly"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"University of Oxford","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b Dupuytren's Disease Study Results in The Lancet Rheumatology","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intra-Nodular Injection","sponsorNew":"180 Life Sciences \/ University of Oxford","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ University of Oxford"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioRestorative Therapies Hosts Principal Investigator Meeting for its BRTX-100 Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"BRTX-100","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Intradiscal Injection","sponsorNew":"Biorestorative Therapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Not Applicable"},{"orgOrder":0,"company":"BriOri BioTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gordon Robert Alton, PhD Joins BriOri BioTech as COO to Develop Patented Topical Formulation of Vioxx\u00ae Providing Those Suffering with Osteoarthritis a Long Lasting Non-Opioid Option for Pain Relief","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Rofecoxib","moa":"COX-2","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"BriOri BioTech","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"BriOri BioTech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BriOri BioTech \/ Not Applicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entera Bio Files Patent Applications for Inventions that Optimize its Platform Technology for Oral Delivery of Large Molecule Therapeutics","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Genascence","sponsor":"Pacira BioSciences","pharmaFlowCategory":"D","amount":"$10.5 million","upfrontCash":"Undisclosed","newsHeadline":"Genascence Announces First Close in Series A Financing led by Pacira BioSciences and Expands Board of Directors and Scientific Advisory Board","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Series A Financing","leadProduct":"sc-rAAV2.5IL-1Ra","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Genascence","amount2":0.01,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.01,"dosageForm":"Inhalation","sponsorNew":"Genascence \/ Pacira BioSciences","highestDevelopmentStatusID":"8","companyTruncated":"Genascence \/ Pacira BioSciences"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scilex, a Sorrento Company, Highlights Safety Data From Phase 1 Trial of SP-104, a Proprietary Low Dose Naltrexone for Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Naltrexone Hydrochloride","moa":"Opioid receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Scilex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Delayed Release Capsule","sponsorNew":"Scilex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Scilex Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Kindeva Drug Delivery","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virpax Pharmaceuticals Selects Kindeva Drug Delivery as Development Partner for Diclofenac pMDI Commercialization","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"Diclofenac Epolamine","moa":"COX1\/COX2","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Virpax Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Virpax Pharmaceuticals \/ Kindeva","highestDevelopmentStatusID":"5","companyTruncated":"Virpax Pharmaceuticals \/ Kindeva"},{"orgOrder":0,"company":"Amazentis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Milestone Clinical Study Shows Postbiotic Urolithin A (Mitopure\u2122) Improves Muscle Strength and Exercise Performance in Middle Aged Adults","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Urolithin A","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Amazentis","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Amazentis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amazentis \/ Not Applicable"},{"orgOrder":0,"company":"Bioiberica","sponsor":"ByHealth","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"New Partnership With ByHealth in China","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Partnership","leadProduct":"Undenatured Type II Collagen","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Bioiberica","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bioiberica \/ ByHealth","highestDevelopmentStatusID":"12","companyTruncated":"Bioiberica \/ ByHealth"},{"orgOrder":0,"company":"Bioiberica","sponsor":"Apsen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bioiberica and Apsen Reinforce Partnership with New Holistic Mobility Product\u2013Motilex HA","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Partnership","leadProduct":"Hyaluronic Acid","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Bioiberica","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Bioiberica \/ Apsen","highestDevelopmentStatusID":"12","companyTruncated":"Bioiberica \/ Apsen"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Bioiberica","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nestl\u00e9 Health Science Partners with Bioiberica to Deliver Innovative Nutrition in Joint Health and Mobility","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Partnership","leadProduct":"Hyaluronic Acid","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nestle Health Sciences SA \/ Bioiberica","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Bioiberica"},{"orgOrder":0,"company":"Bioiberica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Study Reveals Bioiberica's Dermial\u00ae Delivers Superior Benefits for Skin Health","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"Hyaluronic Acid","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Bioiberica","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bioiberica \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bioiberica \/ Not Applicable"},{"orgOrder":0,"company":"Bioiberica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Study Further Validates Bioiberica\u2019s B-2cool\u00ae Native Type II Collagen as Trusted Source for Holistic Mobility Solutions","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"chondroitin sulphate","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Bioiberica","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bioiberica \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bioiberica \/ Not Applicable"},{"orgOrder":0,"company":"Bioiberica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bioiberica Rebrands Its Range of Nutraceutical Ingredients for Healthcare","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Chondroitin Sulfate Sodium","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Bioiberica","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Bioiberica \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bioiberica \/ Not Applicable"},{"orgOrder":0,"company":"Bioiberica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Laboratorios Ordesa Incorporates B-2cool\u00ae, Bioiberica\u2019s Native Type II Collagen, in Its New Colnatur\u00ae Forte","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Harpagophytum Procumbens Extract","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Bioiberica","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Bioiberica \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Bioiberica \/ Not Applicable"},{"orgOrder":0,"company":"Sparrow Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sparrow Pharmaceuticals Presents New Pharmacological Data on HSD-1 Inhibitor SPI-62 at the 2022 Annual European Congress of Rheumatology","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Prednisolone","moa":"HSD-1","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sparrow Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sparrow Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sparrow Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amneal Launches LYVISPAH\u00ae (baclofen) for Spasticity Related to Multiple Sclerosis and Other Spinal Cord Disorders","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Baclofen","moa":"PMP22 gene overexpression","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Granule","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"University of Alabama","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virios Therapeutics\u2019 Study Featured in Peer-Reviewed Journal Publication Highlighting Association of Herpes Simplex Type 1 Viral Infection with Common Gastrointestinal Disorders, Including in Patients with Comorbid Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Famciclovir","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Pill","sponsorNew":"Virios Therapeutics \/ University of Alabama","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ University of Alabama"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioRestorative Therapies Announces Clinical Site Initiation for the Company\u2019s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"BRTX-100","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biorestorative Therapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Not Applicable"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"180 Life Sciences Provides Update on Correspondence Received from U.K. and U.S. Regulatory Authorities on Pathway for a Therapy That Could Prevent Progression of Early-Stage Dupuytren's Disease","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"180 Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MyMD Pharmaceuticals Advances Phase 2 Multi-Center Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Isomyosamine","moa":"TNF alpha","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Healthy Extracts","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Healthy Extracts\u2019 WHITNEY JOHNS ACTIVE\u2122 Clinically Proven to Enhance Physical Performance by Increasing Nitric Oxide by 73% and Oxygen Consumption by 24%","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"choline","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Healthy Extracts","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Healthy Extracts \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Healthy Extracts \/ Not Applicable"},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endo Provides Top-Line Results from Phase 2 Study of Collagenase Clostridium Histolyticum (CCH) in Participants with Adhesive Capsulitis of the Shoulder","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Collagenase Clostridium Histolyticum","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Endo International","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Endo International \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Endo International \/ Not Applicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fulcrum Therapeutics Enrolls First Patient in Pivotal Global Phase 3 Clinical Trial of Losmapimod for Facioscapulohumeral Muscular Dystrophy (FSHD)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Losmapimod","moa":"p38-alpha\/beta-Mapk","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fulcrum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Amazentis","sponsor":"Scripps Research","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Study Shows Urolithin A (Mitopure\u00ae) Improves Mitochondrial Health, Reduces Joint Cartilage Damage and Alleviates Pain in Osteoarthritis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Urolithin A","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Amazentis","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Amazentis \/ Scripps Research","highestDevelopmentStatusID":"4","companyTruncated":"Amazentis \/ Scripps Research"},{"orgOrder":0,"company":"Accord healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Accord's SONDELBAY\u00ae (teriparatide) is Given Green Light by CHMP","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Biosimilar","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH1R","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Accord healthcare","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Accord healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Accord healthcare \/ Not Applicable"},{"orgOrder":0,"company":"Pluri","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgery","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic PLX-PAD Cell","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Pluri","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pluri \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pluri \/ Not Applicable"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","amount":"$6.5 million","upfrontCash":"Undisclosed","newsHeadline":"180 Life Sciences Corp. Announces $6.5 Million Registered Direct Offering","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"July 2022","year":"2022","type":"Public Offering","leadProduct":"Adalimumab","moa":"TNF","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0.01,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"180 Life Sciences \/ Alliance Global Partners","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Alliance Global Partners"},{"orgOrder":0,"company":"OliPass","sponsor":"Novotech","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OliPass Moves Forward to Second Stage of Phase 2a Trial for Pain Killer OLP-1002","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"OLP-1002","moa":"Selective Nav1.7","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"OliPass","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"OliPass \/ Novotech","highestDevelopmentStatusID":"8","companyTruncated":"OliPass \/ Novotech"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entera Bio Announces Execution of Key Regulatory Milestones for EB613, the First Oral Anabolic Drug Proposed for the Treatment of Osteoporosis; Miranda Toledano Assumes CEO Position","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTHR","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alvotech Initiates a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia and Xgeva","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Denosumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alvotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Not Applicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entera Bio Announces Formation of Clinical and Scientific Advisory Board and Poster Presentation at ASBMR 2022 Annual Meeting","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTHR","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Eden Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Subjects Dosed in Australian Phase I Clinical Study of a Denosumab Biosimilar","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Denosumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Eden Biologics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eden Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Eden Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Eden Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eden Biologics\u2019 Leading Biosimilar Program Receives Phase 3 Approval in Europe","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Denosumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Eden Biologics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eden Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Eden Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Avenue Venture Opportunities Fund","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Rani Therapeutics Enters into $45 Million Loan Agreement to Support Ongoing RaniPill\u00ae Platform Advancement and Clinical Pipeline Development","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Agreement","leadProduct":"Parathyroid Hormone (1-34)","moa":"PTH receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rani Therapeutics \/ Avenue Venture Opportunities Fund","highestDevelopmentStatusID":"6","companyTruncated":"Rani Therapeutics \/ Avenue Venture Opportunities Fund"},{"orgOrder":0,"company":"Radius Health","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Gurnet Point Capital and Patient Square Capital Complete Their Acquisition of Radius Health, Inc.","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2022","year":"2022","type":"Acquisition","leadProduct":"Abaloparatide Acetate","moa":"PTH1 receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Radius Health","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.89000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Radius Health \/ Gurnet Point Capital","highestDevelopmentStatusID":"12","companyTruncated":"Radius Health \/ Gurnet Point Capital"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of RT-102 in Osteoporosis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Parathyroid Hormone (1-34)","moa":"PTH receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rani Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rani Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aptinyx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"NYX-2925","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Aptinyx","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aptinyx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aptinyx \/ Not Applicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Towa Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai Obtains Regulatory Approval for Osteoporosis Treatment Edirol Tablet","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Eldecalcitol","moa":"Vitamin D3 receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Chugai Pharmaceutical \/ Towa Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pharmaceutical \/ Towa Pharmaceutical"},{"orgOrder":0,"company":"Radius Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Radius Health Update on Abaloparatide Transdermal System","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"June 2022","year":"2022","type":"Not Applicable","leadProduct":"Abaloparatide Acetate","moa":"PTH1 receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Radius Health","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Radius Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Radius Health \/ Not Applicable"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kyowa Kirin Receives European Commission Approval for Use of CRYSVITA\u00ae (burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Burosumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Kyowa Kirin","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Kyowa Kirin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kyowa Kirin \/ Not Applicable"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"NIHR","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"180 Life Sciences with the University of Oxford Announce the Enrollment of the First Patient in a Trial of Anti-TNF for People with Early-Stage Frozen Shoulder","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"180 Life Sciences \/ NIHR","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ NIHR"},{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alvotech Initiates Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia\u00ae and Xgeva\u00ae","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2022","year":"2022","type":"Not Applicable","leadProduct":"Denosumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Alvotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ Not Applicable"},{"orgOrder":0,"company":"Pluri","sponsor":"European Union\u2019s Horizon Europe","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"Undisclosed","newsHeadline":"\u20ac7.5 Million Granted to Collaborative PROTO Project led by Charit\u00e9 to Study Pluri\u2019s PLX-PAD Cells for Osteoarthritis Treatment","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Collaboration","leadProduct":"PLX-PAD","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Pluri","amount2":0.01,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Pluri \/ European Union\u2019s Horizon Europe","highestDevelopmentStatusID":"4","companyTruncated":"Pluri \/ European Union\u2019s Horizon Europe"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"DKSH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lupin and DKSH Sign an Exclusive Licensing and Supply Agreement to Market Five Biosimilar Candidates in the Philippines","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Denosumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lupin Ltd \/ DKSH","highestDevelopmentStatusID":"10","companyTruncated":"Lupin Ltd \/ DKSH"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA and Health Canada Clear IND for FSD Pharma to Proceed with Phase 2 Trial of FSD201 for Nociplastic Pain Associated with Idiopathic Mast Cell Activation Syndrome","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Palmitoylethanolamide","moa":"CB2 receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"FSD Pharma","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FSD Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"FSD Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Sparrow Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sparrow Pharmaceuticals Doses First Patient in Phase 2 Clinical Trial of SPI-62 with Prednisolone for Polymyalgia Rheumatica","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Prednisolone","moa":"HSD-1","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sparrow Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Sparrow Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sparrow Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entera Bio Presents Dose Proportional Absorption and Correlation to BMD Clinical Response Data from its Phase 2 Study of EB613 in Post-Menopausal Osteoporosis Patients at the ASBMR 2022 Annual Meeting","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio Ltd \/ Not Applicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASBMR 2022: 3D Modelling of Hip DXA Scans in Postmenopausal Women With Osteoporosis Reveals Superior Improvements in Bone Density of Romosozumab Versus Controls","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Romosozumab","moa":"Sclerostin","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"UCB Pharma S.A \/ Amgen Inc","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma S.A \/ Amgen Inc"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Virios Therapeutics, Inc. Announces Pricing of Public Offering","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Public Offering","leadProduct":"Famciclovir","moa":"HSV-1 DNA polymerase","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0.01,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Virios Therapeutics \/ ThinkEquity","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ ThinkEquity"},{"orgOrder":0,"company":"Altay Therapeutics","sponsor":"SOLVE FSHD","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"SOLVE FSHD Invests US$3 Million in Altay Therapeutics","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2022","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"DUX4 expression","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Discovery","graph3":"Altay Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Altay Therapeutics \/ SOLVE FSHD","highestDevelopmentStatusID":"2","companyTruncated":"Altay Therapeutics \/ SOLVE FSHD"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Virios Therapeutics, Inc. Announces Closing of Public Offering","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Public Offering","leadProduct":"Famciclovir","moa":"HSV-1 DNA polymerase","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0.01,"dosageForm":"Pill","sponsorNew":"Virios Therapeutics \/ ThinkEquity","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ ThinkEquity"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Announces Further Progress on its Biosimilar Pipeline, With Release of Positive Results For Denosumab Integrated Phase I\/III Clinical Trial","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Denosumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sandoz B2B \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B \/ Not Applicable"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virios Therapeutics Announces Top-Line Results from Phase 2b Study of IMC-1 in Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Famciclovir","moa":"HSV-1 DNA polymerase","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Pill","sponsorNew":"Virios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MyMD Pharmaceuticals\u00ae Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1\u00ae as a Therapy for Delaying Aging and Extending Healthy Lifespan","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Isomyosamine","moa":"TNF alpha","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlzeCure Presents New Data on the Anti-Inflammatory Effects of its TrkA-NAM Pain Project at IASP 2022","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"AC-0027838","moa":"TrkA receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"AlzeCure Pharma AB","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"AlzeCure Pharma AB \/ Not Applicable"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tryp Therapeutics Strengthens Intellectual Property Portfolio with Provisional Patent Applications for Fibromyalgia Treatment and for Crystalline Forms of TRP-8803","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tryp Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioRestorative Therapies to Participate in the Roth Inaugural Healthcare Opportunities Conference","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"BRTX-100","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biorestorative Therapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Not Applicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioRestorative Therapies to Present at the Dawson James Securities 7th Annual Small Cap Growth Conference","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"BRTX-100","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biorestorative Therapies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Not Applicable"},{"orgOrder":0,"company":"miRecule","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$430.0 million","upfrontCash":"$30.0 million","newsHeadline":"miRecule Enters into Strategic Collaboration with Sanofi to Accelerate Discovery and Development of a Best-in-Class Antibody-RNA Conjugate to Treat Facioscapulohumeral Muscular Dystrophy (FSHD)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Licensing Agreement","leadProduct":"MC-DX4","moa":"DUX4 expression","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"miRecule","amount2":0.42999999999999999,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.42999999999999999,"dosageForm":"","sponsorNew":"miRecule \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"miRecule \/ Sanofi"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tryp Therapeutics Announces Publication of International PCT Patent Application for the Intravenous Administration of Psilocin and Psilocybin","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tryp Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"U.S. Food and Drug Administration","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Teriparatide","moa":"PTH receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"EnteraBio Ltd","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EnteraBio Ltd \/ U.S. Food and Drug Administration","highestDevelopmentStatusID":"10","companyTruncated":"EnteraBio Ltd \/ U.S. Food and Drug Administration"},{"orgOrder":0,"company":"Bone Biologics","sponsor":"WallachBeth Capital","pharmaFlowCategory":"D","amount":"$5.1 million","upfrontCash":"Undisclosed","newsHeadline":"Bone Biologics Announces Closing of $5,100,000 Underwritten Public Offering","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Public Offering","leadProduct":"NELL-1","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Bone Biologics","amount2":0.01,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"Bone Biologics \/ WallachBeth Capital","highestDevelopmentStatusID":"4","companyTruncated":"Bone Biologics \/ WallachBeth Capital"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fulcrum Therapeutics to Present New Data from the Open Label Extension of Phase 2 ReDUX4 Study at the World Muscle Society (WMS) Congress in Halifax, Canada","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Losmapimod","moa":"p38-alpha\/beta-Mapk","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fulcrum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"SiSaf","sponsor":"CSSi LifeSciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SiSaf's Innovative RNA Therapeutic for Rare Genetic Skeletal Disorders Begins the U.S. Regulatory Process for Orphan Drug Designation","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"SIS-101-ADO","moa":"CLCN7 gene mutation","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"SiSaf","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SiSaf \/ CSSi LifeSciences","highestDevelopmentStatusID":"5","companyTruncated":"SiSaf \/ CSSi LifeSciences"},{"orgOrder":0,"company":"Epic Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Epic Bio Presents Proprietary Gene Expression Modulation System (GEMS) Demonstrating Precise Engineering of DUX4 Gene in Facioscapulohumeral Muscular Dystrophy","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"EPI-321","moa":"DUX4 expression","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Epic Bio","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Epic Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Epic Bio \/ Not Applicable"},{"orgOrder":0,"company":"4Moving Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4Moving Biotech Announces First Patient Enrolled in Phase I Clinical Trial on Osteoarthritis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"4P-004","moa":"GLP-1 receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"4Moving Biotech","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"4Moving Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"4Moving Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Assia Chemical Industries Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva Announces Results from 3-Year Study Assessing the Safety and Tolerability of AUSTEDO\u00ae (deutetrabenazine) Tablets for the Treatment of Chorea Associated with Huntington\u2019s Disease","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"Deutetrabenazine","moa":"VMAT2","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Assia Chemical Industries Ltd","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Assia Chemical Industries Ltd \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Assia Chemical Industries Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Novadip Biosciences","sponsor":"Science Ventures","pharmaFlowCategory":"D","amount":"$88.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novadip Biosciences Raises Additional EUR 40 Million Bringing Total Company Funding to EUR 88 Million","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Series B Financing","leadProduct":"NVD-X3","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Novadip Biosciences","amount2":0.089999999999999997,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Novadip Biosciences \/ Science Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Novadip Biosciences \/ Science Ventures"},{"orgOrder":0,"company":"Epic Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Epic Bio Presents First Data Supporting Persistent and Tunable Gene Activation Using Transient Delivery","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"EPI-321","moa":"DUX4 expression","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Epic Bio","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Epic Bio \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Epic Bio \/ Not Applicable"},{"orgOrder":0,"company":"Anika Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anika\u2019s Cingal\u00ae Successfully Achieves Primary Endpoint in Third Phase III Study","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Sodium Hyaluronate","moa":"Hyaluronic acid","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Anika Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Anika Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Anika Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Osteal Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Osteal Therapeutics, Inc. Completes Enrollment in APEX Phase 2 Clinical Trial of VT-X7 for Periprosthetic Joint Infection","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Vancomycin Hydrochloride","moa":"Cell wall synthesis","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Osteal Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Osteal Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Osteal Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MyMD Pharmaceuticals Announces Publication of Phase 1 Data for Oral TNF-alpha Inhibitor MYMD-1\u00ae in Peer-Reviewed Journal Drug Research","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Isomyosamine","moa":"TNF alpha","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Sparrow Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sparrow Pharmaceuticals Presents Pharmacology Data on SPI-62 at American College of Rheumatology Convergence 2022","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"SPI-62","moa":"HSD-1","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sparrow Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sparrow Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sparrow Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ZYUS Announces Database Lock for its Phase 1 First-in-Human Clinical Trial","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Trichomylin","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"ZYUS Life Sciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ZYUS Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ZYUS Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CORRECTION: Adalimumab Found To Be A Likely Cost-Effective Treatment for Early-Stage Dupuytren\u2019s Disease","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"180 Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MyMD Pharmaceuticals\u00ae Announces Upcoming Presentation of Late-Breaking Data for MYMD-1\u00ae at the 2022 British Society for Immunology (BSI) Congress","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Isomyosamine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Taisho Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transfer and Future Marketing of Osteoporosis Agent Bonviva in Japan","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Ibandronate Sodium","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chugai Pharmaceutical \/ Taisho Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pharmaceutical \/ Taisho Pharmaceutical"},{"orgOrder":0,"company":"Regenexx","sponsor":"Biorestorative Therapies","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioRestorative Therapies Enters Agreement with Regenexx, Granting BRTX Exclusive License Rights for Intellectual Property Related to the Development and Commercialization of its BRTX-100\u00ae Disc Program to Treat Chronic Lumbar Disc Disease","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Agreement","leadProduct":"BRTX-100","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Regenexx","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Regenexx \/ BioRestorative Therapies","highestDevelopmentStatusID":"8","companyTruncated":"Regenexx \/ BioRestorative Therapies"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"180 Life Sciences Provides Update on Progress To Seek Medicines and Healthcare Products Regulatory Agency Marketing Authorization for Anti-TNF Treatment of Early Stage Dupuytren's Contracture","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"180 Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioAge Announces Positive Topline Results for BGE-105 in Phase 1b Clinical Trial Evaluating Muscle Atrophy in Older Volunteers at Bed Rest","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"BGE-105","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"BioAge Labs","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioAge Labs \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioAge Labs \/ Not Applicable"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rani Therapeutics Announces Repeat-Dose Topline Results from RT-102 Phase 1 Study","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Teriparatide","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rani Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rani Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin Launches Authorized Generic Version of PENNSAID\u00ae 2% w\/w in the United States","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Diclofenac Sodium","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Solution","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Towa Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Chugai and Towa Launch Edirol Tablet for Osteoporosis Treatment","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Eldecalcitol","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chugai Pharmaceutical \/ Towa Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pharmaceutical \/ Towa Pharmaceutical"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioAge Hosting Webcast to Discuss Newly Announced Phase 1b Data Demonstrating BGE-105 Significantly Improves Muscle Atrophy in Older Volunteers on Bed Rest and Detail Phase 2 Plans","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"BGE-105","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"BioAge Labs","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"BioAge Labs \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioAge Labs \/ Not Applicable"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"180 Life Sciences Corp. Announces $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2022","year":"2022","type":"Public Offering","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0.01,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"180 Life Sciences \/ Alliance Global Partners","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Alliance Global Partners"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Achieves Enrollment of First 50 Percent of Participants in the RESILIENT Study, a Potentially Pivotal Confirmatory Phase 3 Study of TNX-102 SL for the Management of Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","amount":"$6.0 million","upfrontCash":"Undisclosed","newsHeadline":"180 Life Sciences Corp. Announces Closing of $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2022","year":"2022","type":"Public Offering","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0.01,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"180 Life Sciences \/ Alliance Global Partners","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Alliance Global Partners"},{"orgOrder":0,"company":"Arugula Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arugula Sciences Announces Company Launch with FDA Phase 1 Approval for Osteoarthritis Therapy","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"SIG001","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Arugula Sciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Arugula Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Arugula Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rani Therapeutics Receives Feedback from Pre-IND Meeting with FDA; Provides Pipeline Update","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Parathyroid Hormone (1-34)","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rani Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rani Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virios Therapeutics Announces Scheduling of FDA Meeting in March 2023 to Discuss IMC-1 Fibromyalgia Phase 3 Program","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Famciclovir","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Pill","sponsorNew":"Virios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Canada Royal Enoch Phytomedicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Canada Royal Enoch Phytomedicine Launches Clinical Trial of its Ginseng-Derived Redsenol-1 Plus Noble Ginsenoside Capsules","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Ginsenoside","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Canada Royal Enoch Phytomedicine","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Steroid","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Canada Royal Enoch Phytomedicine \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Canada Royal Enoch Phytomedicine \/ Not Applicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"Fulcrum Therapeutics Announces Pricing of Upsized Public Offering of Common Stock","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Public Offering","leadProduct":"Losmapimod","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0.13,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0.13,"dosageForm":"Tablet","sponsorNew":"Fulcrum Therapeutics \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avidity Biosciences Granted FDA Fast Track Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"AOC 1020","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Avidity Biosciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avidity Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Avidity Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Immunis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunis Recruits Individuals with Muscle Atrophy for Phase 1\/2a Clinical Trial","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"IMM01-STEM","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Immunis","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Immunis \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immunis \/ Not Applicable"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"180 Life Sciences Announces Publication of a Review on the Treatments for Early Stage Dupuytren\u2019s Disease","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"180 Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"FSD Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recruiting Underway in FSD Pharma\u2019s Phase 2 Trial of FSD-PEA (FSD201) for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"Palmitoylethanolamide","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"FSD Pharma","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FSD Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"FSD Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Arugula Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arugula Sciences Announces FDA Approval to Proceed with Phase 1 Study of SIG002, a Perinatal-derived Secretome Product, for the Treatment of Big Toe Osteoarthritis (Hallux Rigidus)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"SIG002","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Arugula Sciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Arugula Sciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Arugula Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Radius Health","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","amount":"$890.0 million","upfrontCash":"$547.0 million","newsHeadline":"Radius Health Announces Agreement to be Acquired by Gurnet Point Capital and Patient Square Capital","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"June 2022","year":"2022","type":"Acquisition","leadProduct":"Abaloparatide Acetate","moa":"PTH1 receptor","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Radius Health","amount2":0.89000000000000001,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.89000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Radius Health \/ Gurnet Point Capital","highestDevelopmentStatusID":"12","companyTruncated":"Radius Health \/ Gurnet Point Capital"},{"orgOrder":0,"company":"Radius Health","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","amount":"$890.0 million","upfrontCash":"$547.0 million","newsHeadline":"Gurnet Point Capital and Patient Square Capital Complete Their Acquisition of Radius Health, Inc.","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"August 2022","year":"2022","type":"Acquisition","leadProduct":"Abaloparatide Acetate","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Radius Health","amount2":0.89000000000000001,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.89000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Radius Health \/ Gurnet Point Capital","highestDevelopmentStatusID":"12","companyTruncated":"Radius Health \/ Gurnet Point Capital"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Biologics License Application For Proposed Biosimilar Denosumab Accepted By US FDA","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Denosumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Sandoz B2B","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sandoz B2B \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sandoz B2B \/ Not Applicable"},{"orgOrder":0,"company":"Osteal Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Osteal Therapeutics Announces First Subject Enrollment in Second Phase 2 Clinical Trial of VT-X7 Combination Product for Treatment of Periprosthetic Joint Infection","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Vancomycin Hydrochloride","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Osteal Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Osteal Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Osteal Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Adge Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adge Pharmaceuticals Secures License To Evaluate Two New Programs In Rare Pediatric Diseases","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Elocalcitol","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"F. Hoffmann-La Roche","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Adge Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"F. Hoffmann-La Roche \/ Adge Pharmaceuticals"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avidity Biosciences Receives FDA Orphan Drug Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"AOC 1020","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Avidity Biosciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avidity Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Avidity Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Axcella Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Axcella Announces FDA IND Clearance Supporting Regulatory Path to Registration of AXA1125 for Long COVID Fatigue","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"AXA1125","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Axcella Health","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Axcella Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Axcella Health \/ Not Applicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entera Bio Announces FDA\u2019s Acceptance of a Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets, as the First Oral Osteoanabolic Treatment of Post-Menopausal Osteoporosis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Teriparatide","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"EnteraBio Ltd","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"EnteraBio Ltd \/ Not Applicable"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"180 Life Sciences Announces Allowance of Claims for a US Patent for Dupuytren Disease Treatment and Application","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"180 Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Describes Emerging Research on the Incidence of Multi-Site Pain Symptoms in Long COVID Patients During Event Titled, \u201cLong COVID: What Will it Take to Accelerate Therapeutic Progress?\u201d","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Katalyst Securities","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"MyMD Announces $15 Million Offering with Existing Investors","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Public Offering","leadProduct":"MYMD-1","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0.02,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Katalyst Securities","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ Katalyst Securities"},{"orgOrder":0,"company":"AnnJi Pharmaceutical","sponsor":"Avenue Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$3.0 million","newsHeadline":"Avenue Therapeutics Enters into a Transformational License Agreement with AnnJi Pharmaceutical to Develop and Commercialize AJ201, a First-in-Class Clinical Asset for the Treatment of Spinal and Bulbar Muscular Atrophy","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Licensing Agreement","leadProduct":"AJ201","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"AnnJi Pharmaceutical","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.25,"dosageForm":"","sponsorNew":"AnnJi Pharmaceutical \/ Avenue Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"AnnJi Pharmaceutical \/ Avenue Therapeutics"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MyMD Pharmaceuticals\u00ae Announces Upcoming Presentation of Preclinical Rheumatoid Arthritis Data for Oral TNF-\u03b1 Inhibitor MYMD-1\u00ae at the Society of Toxicology 2023 Annual Meeting","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Not Applicable","leadProduct":"MYMD-1","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Organogenesis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Organogenesis Reports Positive Interim Analysis of Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Cryopreserved Amniotic Suspension Allograft","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Organogenesis","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Organogenesis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Organogenesis \/ Not Applicable"},{"orgOrder":0,"company":"AnnJi Pharmaceutical","sponsor":"Avenue Therapeutics","pharmaFlowCategory":"D","amount":"$253.0 million","upfrontCash":"$3.0 million","newsHeadline":"AnnJi Pharmaceutical Announced A Licensing Agreement With Avenue Therapeutics To Develop And Commercialize AJ201, A First-In-Class Clinical Asset For The Treatment Of Kennedy's Disease","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Licensing Agreement","leadProduct":"AJ201","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"AnnJi Pharmaceutical","amount2":0.25,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.25,"dosageForm":"","sponsorNew":"AnnJi Pharmaceutical \/ Avenue Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"AnnJi Pharmaceutical \/ Avenue Therapeutics"},{"orgOrder":0,"company":"Sparrow Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sparrow Pharmaceuticals Expands Phase 2 Clinical Trial of SPI-62 with Prednisolone for Polymyalgia Rheumatica with Second Cohort","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"Prednisolone","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sparrow Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sparrow Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sparrow Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Altamira Therapeutics\u2019 SemaPhore RNA Delivery Platform Drives Effective Treatment of Osteoarthritis with mRNA in Animal Model","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"DNA-methyltransferase 3 Beta mRNA","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Altamira Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Altamira Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Altamira Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioSenic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioSenic Delivers a New Post-Hoc Analysis of Its Phase III JTA-004 trial on Knee Osteo-Arthritis with Positive Action on The Most Severely Affected Patient Population","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"JTA-004","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"BioSenic","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BioSenic \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioSenic \/ Not Applicable"},{"orgOrder":0,"company":"OliPass","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nav1.7 Selective Inhibitor OLP-1002 Shows Strong Efficacy and Long Therapeutic Duration according to Interim Findings from a Phase 2a Study in OA Patients","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"OLP-1002","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"OliPass","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"OliPass \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OliPass \/ Not Applicable"},{"orgOrder":0,"company":"Radius Health","sponsor":"Theramex","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Theramex Enters Into an Exclusive Licensing Agreement With Radius Health Inc, to Commercialise ELADYNOS\u00ae \u25bcin the European Economic Area, the United Kingdom, Australia and Brazil","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Abaloparatide Acetate","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Radius Health","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Radius Health \/ Theramex","highestDevelopmentStatusID":"12","companyTruncated":"Radius Health \/ Theramex"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Ethicann Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Catalent and Ethicann Sign Development and License Agreement for New Fast-Dissolve Cannabinoid-Based Treatments","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Cannabinoid","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Catalent Pharma Solutions \/ Ethicann Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Catalent Pharma Solutions \/ Ethicann Pharmaceuticals"},{"orgOrder":0,"company":"Exothera","sponsor":"Remedium","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Remedium and Exothera Partner On Scale-up And Demonstration Runs For AAV2-FGF18","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Collaboration","leadProduct":"RMD 1101","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Exothera","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Exothera \/ Remedium","highestDevelopmentStatusID":"4","companyTruncated":"Exothera \/ Remedium"},{"orgOrder":0,"company":"AKL Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Data by AKL Therapeutics Suggests Investigational Oral Osteoarthritis Drug APPA May Have a Promising Senotherapeutic Effect with Potential in Other Diseases of Ageing","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"APPA","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"AKL Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AKL Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AKL Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Systemic Lupus Erythematosus","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"CABA-201","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cabaletta Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta Bio \/ Not Applicable"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"180 Life Sciences Corp. Announces $3 Million Registered Direct Offering and Concurrent Private Placement","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Public Offering","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"180 Life Sciences \/ Alliance Global Partners","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Alliance Global Partners"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entera Bio Provides Guidance from FDA Type D Meeting Related to EB613 Pivotal Program","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Teriparatide","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"EnteraBio Ltd","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"EnteraBio Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Mabwell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The World's Second Approved Biosimilars of Denosumab (MAILISHU)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Denosumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Mabwell","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Mabwell \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mabwell \/ Not Applicable"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"180 Life Sciences Corp. Announces Closing of $3 Million Registered Direct Offering and Concurrent Private Placement","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Public Offering","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"180 Life Sciences \/ Alliance Global Partners","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Alliance Global Partners"},{"orgOrder":0,"company":"Paradigm Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Australia's Paradigm Biopharmaceuticals Says Phase 2 Trial in Osteoarthritis Shows Signs of Disease Modification at 6-Month Follow-Up","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Pentosan Polysulfate Sodium","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Paradigm Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Paradigm Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Paradigm Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MyMD Pharmaceuticals\u00ae Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1\u00ae as a Therapy for Delaying Aging and Extending Healthy Lifespan","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Isomyosamine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Expedites Fibromyalgia and Chronic Migraine Programs","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable"},{"orgOrder":0,"company":"Epic Bio","sponsor":"Solve FSHD","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SOLVE FSHD Invests in Epic Bio for The Development of A Novel Treatment for Facioscapulohumeral Muscular Dystrophy","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Financing","leadProduct":"EPI-321","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Epic Bio","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Epic Bio \/ Solve FSHD","highestDevelopmentStatusID":"5","companyTruncated":"Epic Bio \/ Solve FSHD"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Lifesciences Gets Final Approval from The US FDA to Market Estradiol Transdermal System","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Estradiol","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Hormone","amount2New":0,"dosageForm":"Patch","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"Longeveron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Longeveron Announces First Patient Dosed in Phase 2 Clinical Trial of Lomecel-B\u2122 for Aging-Related Frailty in Japan","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Longeveron Mesenchymal Stem Cell","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Longeveron","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Longeveron \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Longeveron \/ Not Applicable"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virios Therapeutics Announces Initial FDA Feedback on Proposed IMC-1 Phase 3 Program for Treatment of Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"Famciclovir","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Pill","sponsorNew":"Virios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Osteoarthritis Candidate MM-II Showed Durable Pain Relief in Global Phase 2b Study","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"MM-II","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Not Applicable"},{"orgOrder":0,"company":"Oncocross","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncocross Completes Phase I Global Clinical Trial of OC514, Treatment for Sarcopenia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"OC514","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Oncocross","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Oncocross \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Oncocross \/ Not Applicable"},{"orgOrder":0,"company":"SiSaf","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants SiSaf\u2019s Innovative siRNA Therapy SIS-101-ADO Orphan Drug Designation and Rare Pediatric Disease Designation for the Treatment of Autosomal Dominant Osteopetrosis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"SIS-101-ADO","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"SiSaf","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SiSaf \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"SiSaf \/ Not Applicable"},{"orgOrder":0,"company":"Biophytis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biophytis Has Filed with the EMA for Authorization to Initiate SARA-31 Phase 3 Study in Sarcopenia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"20-Hydroxyecdysone","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biophytis","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biophytis \/ Not Applicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transcenta Announces Encouraging Phase I Clinical Data of TST002 (Blosozumab) in Chinese Patients with Reduced Bone Mineral Density","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Blosozumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta Holding \/ Not Applicable"},{"orgOrder":0,"company":"BioSenic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioSenic Reacquires Global IP Rights and Provides Update On JTA-004 Development","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Clonidine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"BioSenic","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BioSenic \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BioSenic \/ Not Applicable"},{"orgOrder":0,"company":"Cayman Chemical Company Inc","sponsor":"NIDCR","pharmaFlowCategory":"D","amount":"$1.7 million","upfrontCash":"Undisclosed","newsHeadline":"Cayman Receives Grant to Evaluate Use of KMN-159 to Accelerate Dental Implant Osseointegration","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","year":"2021","type":"Funding","leadProduct":"Collagen","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Cayman Chemical Company Inc","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Cayman Chemical Company Inc \/ NIDCR","highestDevelopmentStatusID":"4","companyTruncated":"Cayman Chemical Company Inc \/ NIDCR"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Marketing Authorization Applications For Proposed Biosimilar Denosumab Accepted By EMA","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Denosumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Sandoz B2B","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sandoz B2B \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sandoz B2B \/ Not Applicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ferring Announces Positive Topline Phase 3 Results for SI-6603, an Investigational Treatment for Lumbar Disc Herniation","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Condoliase","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Ferring Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Ferring Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ferring Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"EffRx Pharmaceuticals","sponsor":"Abiogen Pharma S.p.A","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Abiogen Pharma Completes the Acquisition of EffRx Pharmaceuticals","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2023","year":"2023","type":"Acquisition","leadProduct":"Alendronate Sodium","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"EffRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Effervescent","sponsorNew":"EffRx Pharmaceuticals \/ Abiogen Pharma S.p.A","highestDevelopmentStatusID":"12","companyTruncated":"EffRx Pharmaceuticals \/ Abiogen Pharma S.p.A"},{"orgOrder":0,"company":"Levolta Pharmaceuticals","sponsor":"Tabuk Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Levolta Pharmaceuticals Partners with Tabuk Pharmaceuticals for Commercialization of Investigational Osteoarthritis Therapy in Middle East and Africa","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II\/ Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Zoledronic Acid Derivative","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"Levolta Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Levolta Pharmaceuticals \/ Tabuk Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Levolta Pharmaceuticals \/ Tabuk Pharmaceuticals"},{"orgOrder":0,"company":"Silo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Silo Pharma Signs Agreement to Develop First-in-Class Ketamine Implant Therapeutic","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Silo Pharma","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Silo Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Silo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"FSHD Society","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Advocacy and Industry Partners Launch New Global Coalition to Speed Delivery of New Therapies for Facioscapulohumeral Muscular Dystrophy (FSHD)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Collaboration","leadProduct":"Losmapimod","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fulcrum Therapeutics \/ FSHD Society","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ FSHD Society"},{"orgOrder":0,"company":"Silo Pharma","sponsor":"Zylo Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Psychedelics Company Silo Pharma Working on Time-Release and Dosage Ketamine Implant and Topical, Hoping to Deliver Steady Pain Relief for Four Million Fibromyalgia Sufferers","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Silo Pharma","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Implant","sponsorNew":"Silo Pharma \/ Zylo Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Silo Pharma \/ Zylo Therapeutics"},{"orgOrder":0,"company":"Sanofi","sponsor":"CORONA remedies","pharmaFlowCategory":"D","amount":"$28.5 million","upfrontCash":"Undisclosed","newsHeadline":"CORONA Remedies Buys India's Ortho Brand Myoril","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Acquisition","leadProduct":"Thiocolchicoside","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Sanofi","amount2":0.029999999999999999,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"Sanofi \/ CORONA remedies","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ CORONA remedies"},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eupraxia Pharmaceuticals Reports Positive Topline Data in its Phase 2b Osteoarthritis Trial with EP-104IAR","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Fluticasone Propionate","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Eupraxia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Steroid","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eupraxia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Eupraxia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Nationwide Children\u2019s Hospital","sponsor":"Solve FSHD","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SOLVE FSHD Announces New Collaborative Research Grants to Accelerate Novel Potential Therapeutics for Facioscapulohumeral Muscular Dystrophy (FSHD)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Nationwide Children\u2019s Hospital","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nationwide Children\u2019s Hospital \/ Solve FSHD","highestDevelopmentStatusID":"4","companyTruncated":"Nationwide Children\u2019s Hospital \/ Solve FSHD"},{"orgOrder":0,"company":"Biophytis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biophytis Seeks US FDA Approval to Initiate SARA-31 Phase 3 Study in Sarcopenia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"20-Hydroxyecdysone","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biophytis","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biophytis \/ Not Applicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1\/2 Study of ARO-DUX4 for Facioscapulohumeral Muscular Dystrophy","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"ARO-DUX4","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Arrowhead Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Arrowhead Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Arrowhead Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transcenta Anti-sclerostin Monoclonal Antibody TST002 (Blosozumab) Received Approval from China CDE to Initiate Phase II Clinical Trial in Patients with Reduced Bone Mineral Density","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Blosozumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Transcenta Holding","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Transcenta Holding \/ Not Applicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF-\u03b1 Inhibitor MYMD-1 in Sarcopenia\/Age-Related Frailty","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Isomyosamine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MyMD Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Completes Enrollment in Potentially NDA-Enabling Phase 3 RESILIENT Trial of TNX-102 SL for Management of Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable"},{"orgOrder":0,"company":"Immunis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Immunis\u2019 Phase 1\/2a Clinical Trial Approved by Data Safety and Monitoring Board to Proceed with Dose Escalation","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"IMM01-STEM","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Immunis","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Immunis \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Immunis \/ Not Applicable"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"180 Life Sciences Provides Update on Regulatory Approval Process in the UK and US for Dupuytren\u2019s Disease Treatment; Continues Consultations with the UK MHRA and Initiates a Type C Meeting Request with the US FDA","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"180 Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Completes Clinical Phase of PREVAIL Proof-of-Concept Study of TNX-102 SL for the Treatment of Fibromyalgia-Type Long COVID","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable"},{"orgOrder":0,"company":"Virios Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Virios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Famciclovir","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Virios Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Pill","sponsorNew":"Virios Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Virios Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"180 Life Sciences Corp. Announces Pricing of $3 Million Public Offering","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Public Offering","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"180 Life Sciences \/ Alliance Global Partners","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Alliance Global Partners"},{"orgOrder":0,"company":"180 Life Sciences","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"180 Life Sciences Corp. Announces Closing of $3 Million Public Offering","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Public Offering","leadProduct":"Adalimumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II\/ Phase III","graph3":"180 Life Sciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II\/ Phase III","highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"180 Life Sciences \/ Alliance Global Partners","highestDevelopmentStatusID":"9","companyTruncated":"180 Life Sciences \/ Alliance Global Partners"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announces Topline Results from Phase 2 PREVAIL Proof-of-Concept Study of TNX-102 SL for the Management of Fibromyalgia-Type Long COVID","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable"},{"orgOrder":0,"company":"SpineThera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SpineThera Announces Breakthrough Market Research Results for SX600 in the Management of Sciatica Pain","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"SpineThera","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"SpineThera \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"SpineThera \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Resiniferatoxin","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Sorrento Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fulcrum Announces Completion of Enrollment in the Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Losmapimod","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fulcrum Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sparrow Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sparrow Pharmaceuticals Initiates Third Cohort in PROST!, Phase 2 Clinical Trial of SPI-62 with Prednisolone for Polymyalgia Rheumatica","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Prednisolone","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sparrow Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Sparrow Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Sparrow Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"EffRx Pharmaceuticals","sponsor":"Radius Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EffRx Pharmaceuticals Signs Exclusive Licensing Agreement with Radius Health to Commercialize BINOSTO\u00ae in the United States","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Alendronate Sodium","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"EffRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet, Effervescent","sponsorNew":"EffRx Pharmaceuticals \/ Radius Health","highestDevelopmentStatusID":"12","companyTruncated":"EffRx Pharmaceuticals \/ Radius Health"},{"orgOrder":0,"company":"Saol therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Saol Therapeutics Announces Completion of Enrollment in Both the Phase II COMPASS Osteoarthritis Knee Pain Trial and the Phase II RAISE Limb Spasticity Trial","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"SL-1002","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Saol therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Saol therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Saol therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Biophytis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biophytis Obtains FDA Authorization to Initiate the SARA-31 Phase 3 Study in Sarcopenia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"20-Hydroxyecdysone","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biophytis","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Hormone","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Biophytis \/ Not Applicable"},{"orgOrder":0,"company":"Rejuvenate Biomed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rejuvenate Biomed Announces Positive Results from Phase 1b Clinical Trial with RJx-01 in Sarcopenia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Galantamine Hydrobromide","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Rejuvenate Biomed","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Rejuvenate Biomed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rejuvenate Biomed \/ Not Applicable"},{"orgOrder":0,"company":"Ascendia Pharmaceuticals","sponsor":"Ampio Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ampio Selects Ascendia Pharmaceuticals, Inc. to Provide CDMO Services to Support Clinical Development of OA-201","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Agreement","leadProduct":"OA-201","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Ascendia Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ascendia Pharmaceuticals \/ Ampio Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Ascendia Pharmaceuticals \/ Ampio Pharmaceuticals"},{"orgOrder":0,"company":"Mabxience","sponsor":"Amneal Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amneal Adds Two Denosumab Biosimilars to U.S. Pipeline, Expanding Oncology Portfolio","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2023","year":"2023","type":"Acquisition","leadProduct":"Denosumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Mabxience","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mabxience \/ Amneal Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Mabxience \/ Amneal Pharmaceuticals"},{"orgOrder":0,"company":"4Moving Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"4Moving Biotech Completes the Recruitment of Its Phase I Clinical Trial in Patients With Knee Osteoarthritis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Liraglutide","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"4Moving Biotech","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"4Moving Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"4Moving Biotech \/ Not Applicable"},{"orgOrder":0,"company":"L2P Research","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"L2P Research Labs Awarded NIH SBIR Grant for Arthritis, Musculoskeletal and Skin Diseases Research","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Discovery","graph3":"L2P Research","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"L2P Research \/ National Institutes of Health","highestDevelopmentStatusID":"2","companyTruncated":"L2P Research \/ National Institutes of Health"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scilex Holding Company Announces Positive Type C Meeting with the FDA and Reaches Agreement on Path Forward to File an NDA for SP-102 (SEMDEXATM) in Lumbosacral Radicular Pain (Sciatica)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Scilex Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Steroid","amount2New":0,"dosageForm":"Injection","sponsorNew":"Scilex Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Scilex Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Completes Clinical Stage of Phase 3 RESILIENT Study of TNX-102 SL for the Management of Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable"},{"orgOrder":0,"company":"OliPass","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OliPass Discloses Painful but Hilarious Clinical Findings from a Phase 2a Trial in OA Patients with Nav1.7 Selective Inhibitor OLP-1002","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"OLP-1002","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"OliPass","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"OliPass \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"OliPass \/ Not Applicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for Osteoporosis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Teriparatide","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"EnteraBio Ltd","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"EnteraBio Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Genascence","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genascence Announces Initiation of Phase 1b Clinical Trial of GNSC-001 Gene Therapy for Knee Osteoarthritis (OA)","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"sc-rAAV2.5IL-1Ra","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Genascence","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genascence \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Genascence \/ Not Applicable"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tryp Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial for the Treatment of Fibromyalgia at The University of Michigan","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Controlled Substance","amount2New":0,"dosageForm":"","sponsorNew":"Tryp Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I\/II Trial Evaluating Allocetra in up to 160 Patients with Moderate to Severe Knee Osteoarthritis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia and Xgeva","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Denosumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Alvotech \/ Not Applicable"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"CABA-201","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta Bio \/ Not Applicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlzeCure Selects Drug Candidate and Enters Next Phase of Development with TrkA-NAM ACD137 Against Severe Pain","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"ACD137","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"AlzeCure Pharma AB","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"AlzeCure Pharma AB \/ Not Applicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Satellos Announces Promising Preliminary Data in Facioscapulohumeral Muscular Dystrophy","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"SAT-3247","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Satellos Bioscience","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Satellos Bioscience \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Satellos Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable"},{"orgOrder":0,"company":"AliveGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AliveGen Announces Successful Completion of Phase 1b Multiple-Ascending Dose Clinical Trial for ALG-801","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"ALG-801","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"AliveGen","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AliveGen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AliveGen \/ Not Applicable"},{"orgOrder":0,"company":"CytoMed Therapeutics","sponsor":"Sengkang General Hospital","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Collaboration","leadProduct":"Mesenchymal Stem Cell Therapy","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Discovery","graph3":"CytoMed Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"CytoMed Therapeutics \/ Sengkang General Hospital","highestDevelopmentStatusID":"2","companyTruncated":"CytoMed Therapeutics \/ Sengkang General Hospital"},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Raymond James Ltd","pharmaFlowCategory":"D","amount":"$33.9 million","upfrontCash":"Undisclosed","newsHeadline":"Eupraxia Pharmaceuticals Announces Closing of Overnight Marketed Offering for Gross Proceeds of C$33.9 Million","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Public Offering","leadProduct":"Fluticasone Propionate","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Eupraxia Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Steroid","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Eupraxia Pharmaceuticals \/ Raymond James Ltd","highestDevelopmentStatusID":"8","companyTruncated":"Eupraxia Pharmaceuticals \/ Raymond James Ltd"},{"orgOrder":0,"company":"Almac Group","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tonix Pharmaceuticals Announces Selection of Two Contract Manufacturing Organizations for the Launch and Commercial Manufacture of Tonmya, for the Management of Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Agreement","leadProduct":"Cyclobenzaprine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Almac Group","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Almac Group \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"10","companyTruncated":"Almac Group \/ Tonix Pharmaceuticals Holding Corp"},{"orgOrder":0,"company":"Celularity","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"PDA-002","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"Celularity","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Celularity \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Celularity \/ Not Applicable"},{"orgOrder":0,"company":"Relation Therapeutics","sponsor":"DCVC","pharmaFlowCategory":"D","amount":"$60.0 million","upfrontCash":"Undisclosed","newsHeadline":"Relation Therapeutics Secures $35 million of New Seed Financing Led by DCVC and Co-Lead NVentures, NVIDIA's Venture Arm","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Discovery","graph3":"Relation Therapeutics","amount2":0.059999999999999998,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Relation Therapeutics \/ DCVC","highestDevelopmentStatusID":"2","companyTruncated":"Relation Therapeutics \/ DCVC"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stelis Receives a Positive Recommendation From European Medicines Agency (EMA) granting Market Authorization for KaulivTM, a Recombinant Human Teriparatide Biosimilar to Treat Osteoporosis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Biosimilar","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Teriparatide","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Pharma Science \/ Not Applicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides Receives USFDA Approval for Pregabalin Capsules","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Pregabalin","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Pharma Science \/ Not Applicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Teriparatide","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Norgine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Norgine Receives Positive ChMP Opinion Recommending Approval of NPJ5008 (dantrolene sodium hemiheptahydrate) for the Treatment of Malignant Hyperthermia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Dantrolene","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Norgine","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Norgine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Norgine \/ Not Applicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","amount":"$144.0 million","upfrontCash":"$30.0 million","newsHeadline":"Tonix Pharmaceuticals Announces Registered Direct Offering of up to $144 Million","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Public Offering","leadProduct":"Cyclobenzaprine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0.14000000000000001,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0.14000000000000001,"dosageForm":"Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Alliance Global Partners"},{"orgOrder":0,"company":"Avicanna","sponsor":"Bryden Stokes Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Avicanna Expands its Medical Cannabis Brand RHO Phyto into the Caribbean Region with Initial Export to Barbados","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Partnership","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Avicanna","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Avicanna \/ Bryden Stokes Limited","highestDevelopmentStatusID":"4","companyTruncated":"Avicanna \/ Bryden Stokes Limited"},{"orgOrder":0,"company":"Rho","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tonix Pharmaceuticals Announces Engagement of Rho as CRO to Support Submission of New Drug Application to the FDA for Approval of Tonmya for the Management of Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Collaboration","leadProduct":"Cyclobenzaprine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Rho","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rho \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"10","companyTruncated":"Rho \/ Tonix Pharmaceuticals Holding Corp"},{"orgOrder":0,"company":"Genflow Biosciences","sponsor":"Revatis SA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Genflow Biosciences Partners with Revatis SA and EXO Biologics in Groundbreaking Aging Research, Fueled by Two Major Research Grants","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Discovery","graph3":"Genflow Biosciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genflow Biosciences \/ Revatis SA","highestDevelopmentStatusID":"2","companyTruncated":"Genflow Biosciences \/ Revatis SA"},{"orgOrder":0,"company":"Eupraxia Pharmaceuticals","sponsor":"Raymond James Ltd","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Eupraxia Pharmaceuticals Announces Overnight Marketed Offering of Approximately $30 Million","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Public Offering","leadProduct":"Fluticasone Propionate","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Eupraxia Pharmaceuticals","amount2":0.029999999999999999,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Steroid","amount2New":0.029999999999999999,"dosageForm":"Sustained-Release","sponsorNew":"Eupraxia Pharmaceuticals \/ Raymond James Ltd","highestDevelopmentStatusID":"8","companyTruncated":"Eupraxia Pharmaceuticals \/ Raymond James Ltd"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva Announces Approval of a Generic Version of Forteo\u00ae (teriparatide injection), in the U.S.","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Teriparatide","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharmaceutical Industries \/ Not Applicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera's Next Generation Oral Peptide Platform","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Teriparatide","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"EnteraBio Ltd","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"EnteraBio Ltd \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"EnteraBio Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Ambio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ambio Announces US FDA Approval of a Generic Version of Forteo\u00ae (Teriparatide Injection) for Its Partner Apotex","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Teriparatide","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Ambio","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ambio \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ambio \/ Not Applicable"},{"orgOrder":0,"company":"Levicept","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Levicept Completes Recruitment in Phase II Clinical Trial of Neurotrophin Modulator LEVI-04","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"LEVI-04","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Levicept","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Levicept \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Levicept \/ Not Applicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hope On The Horizon: Tonix Pharmaceuticals (NASDAQ:TNXP) Could Be On the Cusp of Changing Fibromyalgia Treatment Options With TNX-102 SL","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Hope For Fibromyalgia Patients: Tonix Details Results Of Second Successful Phase 3 Trial And Plans To File For FDA Approval","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable"},{"orgOrder":0,"company":"Nuvig Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nuvig Initiates Clinical Development of Next-Generation Immune Modulator NVG-2089","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"NVG-2089","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Nuvig Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Nuvig Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nuvig Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Ampio Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ampio Provides Update on Results from Pre-IND Enabling Studies","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"OA-201","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Ampio Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ampio Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Ampio Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Selects EVERSANA\u00ae to Support Launch Strategy and Commercialization Planning of Tonmya for the Management of Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable"},{"orgOrder":0,"company":"Persica Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Persica Pharmaceuticals Completes Recruitment into Modic Trial Assessing Efficacy of PP353, to Treat Chronic Lower Back Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"PP353","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Persica Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Persica Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Persica Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Enekinragene Inzadenovec","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Pacira BioSciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Pacira BioSciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pacira BioSciences \/ Not Applicable"},{"orgOrder":0,"company":"Cayman Pharma s.r.o","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cayman Update on its Dental Implant candidate KMN-159 for Osseointegration","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"KMN-159","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Cayman Pharma s.r.o","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cayman Pharma s.r.o \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Cayman Pharma s.r.o \/ Not Applicable"},{"orgOrder":0,"company":"Vaxxinity","sponsor":"University of Florida","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2024","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Vaxxinity","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Vaxxinity \/ University of Florida","highestDevelopmentStatusID":"4","companyTruncated":"Vaxxinity \/ University of Florida"},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ZYUS Life Sciences Corporation Announces Positive Phase I Clinical Trial Results for Trichomylin\u00ae Softgels","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"ZYUS Life Sciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"ZYUS Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ZYUS Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Apotex Fermentation Inc.","sponsor":"Ambio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Apotex Corp. Launches Teriparatide Injectable for Osteoporosis Treatment in the United States","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Peptide","productStatus":"Approved","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Teriparatide","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Apotex Fermentation Inc.","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apotex Fermentation Inc. \/ Ambio","highestDevelopmentStatusID":"12","companyTruncated":"Apotex Fermentation Inc. \/ Ambio"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix Pharmaceuticals Announces Highly Statistically Significant and Clinically Meaningful Topline Results in Second Positive Phase 3 Clinical Trial of TNX-102 SL for the Management of Fibromyalgia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2023","year":"2023","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable"},{"orgOrder":0,"company":"Telomir Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Telomir Pharmaceuticals\u2019 Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Telomir-1","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Telomir Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Telomir Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Telomir Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AlzeCure Presents New Data Regarding the TrkA-NAM Pain Project at IASP 2024","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"ACD137","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"AlzeCure Pharma AB","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"AlzeCure Pharma AB \/ Not Applicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Galen Patient Recruitment","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Partnership","leadProduct":"BRTX-100","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Biorestorative Therapies","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Biorestorative Therapies \/ Galen Patient Recruitment","highestDevelopmentStatusID":"8","companyTruncated":"Biorestorative Therapies \/ Galen Patient Recruitment"},{"orgOrder":0,"company":"Mabwell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MAIWEIJIAN, First Approved Biosimilar of Denosumab (120mg) in China","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Denosumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Mabwell","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mabwell \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mabwell \/ Not Applicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I\/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Avicanna","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$2.1 million","upfrontCash":"Undisclosed","newsHeadline":"Avicanna Announces Closing of Non-brokered Private Placement","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Private Placement","leadProduct":"Cannabidiol","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Avicanna","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Avicanna \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Avicanna \/ Undisclosed"},{"orgOrder":0,"company":"4P-Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$16.0 million","upfrontCash":"Undisclosed","newsHeadline":"4P-Pharma Announces Total Capital of \u20ac15 Million Successfully Secured in Second Closing","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Peptide","productStatus":"Approved","date":"April 2024","year":"2024","type":"Financing","leadProduct":"Liraglutide","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"4P-Pharma","amount2":0.02,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"4P-Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"4P-Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I\/II Trial Evaluating Allocetra\u2122 in Patients with Knee Osteoarthritis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Organogenesis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu\u00ae for Knee Osteoarthritis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Amniotic Suspension Allograft","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Organogenesis","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Organogenesis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Organogenesis \/ Not Applicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$1,055.0 million","upfrontCash":"$80.0 million","newsHeadline":"Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Losmapimod","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Fulcrum Therapeutics","amount2":1.0600000000000001,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":1.0600000000000001,"dosageForm":"Tablet","sponsorNew":"Fulcrum Therapeutics \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Fulcrum Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Alvotech","sponsor":"Dr. Reddy\\'s Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alvotech, Dr. Reddy's Collaborate on Denosumab Biosimilar in US, EU, UK","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2024","year":"2024","type":"Collaboration","leadProduct":"Denosumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alvotech \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Alvotech \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Dawson James Securities, Inc","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tonix Pharmaceuticals Announces Pricing of $4.0 Million Public Offering","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"Cyclobenzaprine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Dawson James Securities, Inc","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Dawson James Securities, Inc"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"Cyclobenzaprine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Dawson James Securities","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Dawson James Securities"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"$5.0 million","newsHeadline":"Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Private Placement","leadProduct":"Allocetra-OTS","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0.02,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.02,"dosageForm":"","sponsorNew":"Enlivex Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex: Positive Interim Data from Phase I\/II Allocetra in Knee Osteoarthritis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Authorized for Phase I\/II Trial of Allocetra in Thumb Osteoarthritis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enlivex Doses First Patient in Phase I\/II Trial of AllocetraTM for Thumb Osteoarthritis","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Allocetra-OTS","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Enlivex Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Enlivex Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Enlivex Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cabaletta Bio: Positive Data from Phase 1\/2 RESET-Myositis and RESET-SLE Trials","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"CABA-201","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Cabaletta Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta Bio \/ Not Applicable"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kyverna's KYV-101 Receives IND Clearance for Stiff-Person Syndrome Phase 2 Trial","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"KYV-101","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Kyverna Therapeutics","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Kyverna Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kyverna Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Genflow Biosciences","sponsor":"Government of Wallonia","pharmaFlowCategory":"D","amount":"$0.4 million","upfrontCash":"Undisclosed","newsHeadline":"Genflow Biosciences PLC Announces Receipt of Grant Funding","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Funding","leadProduct":"Muscle Progenitor Cells","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Discovery","graph3":"Genflow Biosciences","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genflow Biosciences \/ Government of Wallonia","highestDevelopmentStatusID":"2","companyTruncated":"Genflow Biosciences \/ Government of Wallonia"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Organon","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Validates Henlius and Organon Biosimilar Filings for Prolia\u00ae and Xgeva\u00ae","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Denosumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Shanghai Henlius Biotech","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Henlius Biotech \/ Organon","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Henlius Biotech \/ Organon"},{"orgOrder":0,"company":"Alvotech","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alvotech and STADA Add to Strategic Alliance Through Denosumab Partnership","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2024","year":"2024","type":"Partnership","leadProduct":"Denosumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Alvotech \/ STADA Arzneimittel","highestDevelopmentStatusID":"10","companyTruncated":"Alvotech \/ STADA Arzneimittel"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tonix Pharmaceuticals Announces Proposed Public Offering","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"Cyclobenzaprine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Dawson James Securities","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Dawson James Securities"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Dawson James Securities","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tonix Pharmaceuticals Announces Pricing of Approximately $4.0 Million Public Offering","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Public Offering","leadProduct":"Cyclobenzaprine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Dawson James Securities","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Dawson James Securities"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tonix's Tonmya\u2122 for Fibromyalgia Gets Positive Pre-NDA FDA Review","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"Cyclobenzaprine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Not Applicable"},{"orgOrder":0,"company":"MyMD Pharmaceuticals","sponsor":"PharmaCyte Biotech","pharmaFlowCategory":"D","amount":"$7.0 million","upfrontCash":"Undisclosed","newsHeadline":"PharmaCyte Biotech Makes $7 Million Investment in MyMD for Inflammatory Disease","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Financing","leadProduct":"Isomyosamine","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"MyMD Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0.01,"dosageForm":"","sponsorNew":"MyMD Pharmaceuticals \/ PharmaCyte Biotech","highestDevelopmentStatusID":"8","companyTruncated":"MyMD Pharmaceuticals \/ PharmaCyte Biotech"},{"orgOrder":0,"company":"Telomir Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Telomir Pharma Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Telomir-1","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Telomir Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Telomir Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Telomir Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"Moebius Medical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sun Pharma-Moebius Injection Shows Pain Relief in Trials","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2024","year":"2024","type":"Not Applicable","leadProduct":"MM-II","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sun Pharmaceutical Industries Limited \/ Moebius Medical","highestDevelopmentStatusID":"8","companyTruncated":"Sun Pharmaceutical Industries Limited \/ Moebius Medical"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Gets EU Approval for Wyost\u00ae and Jubbonti\u00ae Denosumab Biosimilars","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2024","year":"2024","type":"Not Applicable","leadProduct":"Denosumab","moa":"","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved","graph3":"Sandoz B2B","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sandoz B2B \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sandoz B2B \/ Not Applicable"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Details :
USFDA approved generic version of Pregabalin treatment of fibromyalgia. It binds to the alpha2-delta subunit which is involved in anti-nociceptive and antiseizure effects.
Details :
Through the acquisition, Corona Remedies gains right for the leading muscle relaxant brand Myoril (thiocolchicoside) and its extensions such as Myoril Plus (ketoprofen and thiocolchicoside) to treat muscular pain.
Details :
KMN-159 is a potent, stable, and a highly selective EP4 receptor agonist that stimulates osteogenic activity. It is being evaluated for the treatment of osteoporosis.
Details :
USFDA approved biosimilar, Kauliv (human teriparatide hormone), for the treatment of both men and postmenopausal
women with osteoporosis who are at high risk for having broken bones or fractures.
Details :
By partnering with Bioiberica, ByHealth aims to capitalise on the untapped potential of new product development with native type II collagen and respond to the growing number of consumers looking to support their mobility with effective, convenient produ...
Details :
The grant will be used to explore Cayman’s patented small molecule bone repair agent KMN-159 as the active pharmaceutical ingredient (API) in a drug-device combination to improve the mechanical anchorage of dental titanium implants into the jawbone.
Details :
Bioiberica’s native (undenatured) type II collagen, Collavant® n2 (previously b2-Cool®) and the addition of Tendaxion® - a new brand for its tendon health ingredient.
Details :
Breckenridge previously launched Succinylcholine Chloride Injection, USP, 20mg/mL under this agreement, which is now available from Breckenridge as a carton of 25 vials.
Details :
Apsen’s Motilex HA combines two leading ingredients, b-2Cool native type II collagen and Mobilee, patented ingredient that synergistically combines a high concentration of hyaluronic acid with polysaccharides and collagen, to effectively maintain joint...
Details :
Dr. Reddy's Laboratories has launched Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL), Multiple-Dose Vials a therapeutic equivalent generic version of Quelicin® (Succinylcholine Chloride) Injection, 20 mg/mL, approved by the USFDA.
Market Place
Reset All
Strides Pharma Science: Pioneering IP-driven formulations for niche finished dosage forms.